The DOI matches its Crossref record; 349 of the 363 references it cites were found in a registry or an index; 20 of the 40 sources its claims cite were checked for support.
Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.
Open accessAbstract
Updated ISHLT consensus providing a framework for identifying candidates for lung transplantation and accounting for combinations of risk factors in candidacy selection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 of 40 cited sources checked · 4 supported · 0 flagged · accuracy not yet measured
- Background
The paper says the ESC/ERS pulmonary hypertension model uses a multiparametric assessment and avoids nonmodifiable criteria and variable weighting.
“The ESC/ERS model also employs the assessment of risk using a multi-parametric comprehensive analysis of clinical variables.(284) Unlike REVEAL, this model avoids use of any non-modifiable criteria, and does not “weight” the variables according to their relative importance.”
Quote in the paperNot yet classified1 of 1 sources checked- cites [284] Galiè, 2016, Eur Heart J source
Section 6.2.4 calls for a multidimensional, comprehensive assessment, and section 6.2.5 says overall assessment should guide decisions when variables fall into different risk categories. The claim that the model avoids any nonmodifiable criteria is too absolute: both sections say age, sex, and other factors not affected by therapy can modify risk. The passages do not explicitly specify whether variables receive numerical weights. (LLM, conf=0.85)
Experimental — accuracy not yet measured
- Background
The paper says lung transplantation has expanded worldwide because more donors and candidates are now acceptable, and that candidate selection has become more complex.
“This trend reflects the expansion of acceptable donors and candidates made possible by clinical and scientific advances. Far fewer absolute contraindications for lung transplant candidacy exist now, compared to the time of publication of prior versions of this document, making the selection of candidates even more complex.”
Quote in the paperNot yet classified1 of 3 sources checked- cites [2] Orens, 2006, International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
The introduction says advances in technology and medical knowledge prompted updated candidate-selection guidelines, and the Relative contraindications section allows consideration of some candidates previously treated more restrictively. But our copy does not state that lung transplantation expanded worldwide because more donors became acceptable, nor does it explicitly say there are far fewer absolute contraindications than in 1998 or that selection has become more complex for that reason. No page numbers are available in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measured - cites [3] Maurer, 1998, International guidelines for the selection of lung transplant candidates, Transplantation source
- cites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Finding
The paper says frailty is linked to higher waitlist and post-transplant mortality, but frailty measures are not yet settled for listing decisions.
“Frailty, defined as a generalized vulnerability to stressors resulting from the presence of multiple physiologic deficits, is associated with an increased risk of waitlist and post-transplant mortality.(51–53) However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
Quote in the paperNot yet classified2 of 3 sources checked- cites [51] Baldwin, 2017, Refining low physical activity measurement improves frailty assessment in advanced lung disease and survivors of critical illness, Ann Am Thorac Soc source
The Results (page unavailable) link frailty measured with FFP-DASI to increased death or delisting among lung-transplant candidates. The Methods (page unavailable) say participants were censored at transplant, so this study does not support the post-transplant mortality claim. The Abstract says no gold-standard frailty measure exists, but the paper does not specifically address using frailty measures for listing decisions. (LLM, conf=0.90)
Experimental — accuracy not yet measured - cites [52] Singer, 2018, Frailty phenotypes and mortality after lung transplantation: a prospective cohort study, Am J Transplant source
- cites [53] Singer, 2015, Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation, Am J Respir Crit Care Med source
- Finding
The paper says patients with CF remain at risk of short-term mortality even with improved outcomes, and risk rises after FEV1 falls below 30% predicted.
“Despite improved overall outcomes, many individuals with advanced CF lung disease remain at risk of short-term mortality. A 2017 study demonstrated a 10% risk of death each year after reaching an FEV1 < 30%, with many patients dying soon after reaching this threshold.”
Quote in the paperNot yet classified1 of 1 sources checked- cites [245] Ramos, 2017, Heterogeneity in survival in adult patients with cystic fibrosis with FEV1 < 30% of predicted in the United States, Chest source
- Method
The paper says patients must abstain from all tobacco and nicotine products before transplant, verified with serial testing.
“Lung transplant candidates must demonstrate abstinence from use of all tobacco and nicotine products (including nicotine replacement therapy) prior to transplant (e.g. with serial nicotine and cotinine screening).(111)”
Quote in the paperNot yet classified1 of 1 sources checked- cites [111] Hofmann, 2018, Smoking resumption after heart or lung transplantation: a systematic review and suggestions for screening and management, J Thorac Dis source
The Introduction says candidates are normally required to be smoke-free before joining a thoracic-transplant waiting list. But the systematic-screening section recommends cotinine testing at post-transplant follow-ups, not serial nicotine and cotinine testing before transplant. The paper also says nicotine replacement therapy can be used in transplant recipients; it does not establish the claimed pre-transplant ban on all nicotine products. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Finding
The paper says bronchiolitis obliterans syndrome is not mentioned here; ignore.
“Non-CF bronchiectasis represents 2.7% of all lung transplants reported to the ISHLT Registry between 1995–2018.”
Quote in the paperNot yet classified1 of 1 sources checked- cites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant source
The Lung transplantation—Indications section says Table 1 covers transplant indications since January 1995, but the passages available from our copy do not give a figure for non-CF bronchiectasis. Searches for “non-CF bronchiectasis,” “bronchiectasis,” and “2.7%” did not find the claimed proportion; the quoted passages instead discuss other indications and bronchiolitis obliterans syndrome. (LLM, conf=0.70)
Experimental — accuracy not yet measured
- Finding
The paper says LAM transplant can have better post-transplant survival than other advanced lung diseases and that bilateral transplant may be favored when organs are available.
“Lung transplant for LAM is relatively rare; however, it is associated with better post-transplant survival compared to other advanced lung diseases.(1, 303–307)”
Quote in the paperNot yet classified2 of 6 sources checked- cites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant source
The Lung transplantation section (page unavailable) reports that lymphangioleiomyomatosis as an indication for transplantation is favorably associated with survival in a multivariable model. It does not establish that LAM transplantation is relatively rare or recommend bilateral transplantation when organs are available; its favorable association for bilateral transplantation is reported separately, not specifically for LAM. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [303] Ando, 2016, Lung Transplantation for lymphangioleiomyomatosis in Japan, PLoS One source
- cites [304] Khawar, 2019, Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis, J Heart Lung Transplant source
- cites [305] Baldi, 2017, Experience of lung transplantation in patients with lymphangioleiomyomatosis at a Brazilian reference centre, Lung source
- cites [306] Kurosaki, 2020, Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center, Clin Respir J source
- cites [307] Kpodonu, 2005, The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis, J Heart Lung Transplant source
- Finding
The paper says the REVEAL 2.0 score is a strong predictor of mortality and clinical worsening in pulmonary arterial hypertension, but it has not been prospectively validated.
“An updated version of the score, REVEAL 2.0, which incorporates estimated GFR and all-cause hospitalizations within the previous six-months, has emerged as a powerful predictor of mortality and clinical worsening.(285–287) Neither of the REVEAL scores has been validated prospectively.”
Quote in the paperNot yet classified1 of 3 sources checked- cites [285] Benza, 2019, Predicting survival in patients with pulmonary arterial hypertension: The REVEAL Risk Score Calculator 2.0 and comparison with ESC/ERS-Based risk assessment strategies, Chest source
- cites [286] Chakinala, 2018, Impact of declining renal function on outcomes in pulmonary arterial hypertension: a REVEAL registry analysis, J Heart Lung Transplant source
The Discussion describes renal insufficiency as a mortality predictor included in the REVEAL risk score, and the Statistical analysis uses that score for adjustment. Our copy does not address REVEAL 2.0’s predictive performance or prospective validation (searched: REVEAL 2.0, clinical worsening, prospective validation). (LLM, conf=0.75)
Experimental — accuracy not yet measured - cites [287] Frost, 2013, Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis, Chest source
- Finding
The paper says lung volume reduction can help selected COPD patients and may delay the need for transplant.
“Lung volume reduction (LVR), performed by either surgical or bronchoscopic approach, is an option for a subset of COPD patients with advanced emphysema who meet strict selection criteria. These procedures have been associated with improved lung function, exercise capacity, and quality of life.(181–183)”
Quote in the paperNot yet classified3 of 3 sources checked- cites [181] Criner, 2019, Improving lung function in severe heterogenous emphysema with the spiration valve system (EMPROVE). A multicenter, open-label randomized controlled clinical trial, Am J Respir Crit Care Med source
The Scientific Knowledge commentary says lung volume reduction surgery can improve lung function but is limited to eligible patients; the Results report improved lung function and health status after bronchoscopic valve treatment. The Results also say the improvement in exercise capacity was not statistically significant. The claim’s reference to delaying transplant is absent from the verbatim citing sentence and is not established by these passages. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [182] Criner, 2018, A multicenter randomized controlled trial of Zephyr Endobronchial valve treatment in heterogeneous emphysema (LIBERATE), Am J Respir Crit Care Med source
The Introduction and Conclusion (pages not provided) describe surgical and bronchoscopic lung volume reduction as options for carefully selected patients with severe emphysema. The Discussion reports improvements in lung function, exercise capacity, and quality of life. The copy does not say these treatments delay transplantation; that point also does not appear in the verbatim citing sentence. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [183] Fishman, 2003, A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema, N Engl J Med source
The Discussion (p. 2071) reports that lung-volume-reduction surgery increased the chance of improved exercise capacity, lung function, and quality of life, with benefits varying by patient subgroup. The Methods (page not supplied) describe surgical approaches, not bronchoscopic reduction, so this paper does not support the sentence’s extension to both approaches. The citing sentence does not make a transplant-delay claim; the Treatment section reports transplant counts but does not establish that surgery delayed transplantation. (LLM, conf=0.87)
Experimental — accuracy not yet measured
- Background
The paper says the BODE index has been externally validated in at least 13 cohorts and was used in prior ISHLT listing recommendations.
“The BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-min walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation. The BODE index has been cited as the prognostic model of choice by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and it formed the basis for listing recommendations in the 2014 ISHLT candidate selection guidelines. (4, 166–168)”
Quote in the paperNot yet classified1 of 4 sources checked- cites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- cites [166] Celli, 2004, The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease, N Engl J Med source
- cites [167] Bellou, 2019, Prognostic models for outcome prediction in patients with chronic obstructive pulmonary disease: systematic review and critical appraisal, BMJ source
The external validation studies section reports that BODE was externally validated in 13 cohorts. The Principal findings in context section says GOLD uses BODE in clinical decision-making for lung transplantation, but our copy does not say that BODE formed the basis of the 2014 ISHLT listing recommendations. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [168] Disease GIfCOL: Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease: 2020 Report. 2020.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Background
The paper says thoracic malignancy is an uncommon transplant indication and that outcomes data are lacking because many centers abandoned the practice.
“Thoracic malignancy is a rare indication for lung transplant, accounting for only 0.1% of all lung transplants performed between 1995– 2018.(1) Notably, there is an absence of current data describing outcomes of patients transplanted for thoracic malignancy, likely reflecting the abandonment of this practice in many lung transplant centers.”
Quote in the paperNot yet classified1 of 1 sources checked- cites [1] Chambers, 2019, The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match, J Heart Lung Transplant source
The Lung transplantation—Indications section (page unavailable) points to a table of transplant indications but does not state a thoracic-malignancy count or the claimed 0.1% for 1995–2018. Searches for thoracic malignancy and that percentage also found no passage about a lack of outcomes data or centers abandoning the practice. The citation is attached to the first sentence; the latter explanation appears to be the citing authors’ own statement. (LLM, conf=0.70)
Experimental — accuracy not yet measured
- Background
The paper says non-CF bronchiectasis transplant timing is difficult and that FACED and BSI are used to characterize severity and prognosis.
“Determining transplant timing is difficult due to the wide range of etiologies and demographics. Two non-CF bronchiectasis severity assessment tools were developed from the overall population (not limited to those with advanced lung disease): the FACED score [FEV1, Age, Chronic Pseudomonas aeruginosa, Extension to 1–2 lobes, Dyspnea by modified Medical Research Council scale] and the bronchiectasis severity index (BSI), which adds BMI and exacerbation frequency.”
Quote in the paperNot yet classified2 of 2 sources checked- cites [272] Martinez-Garcia, 2014, Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score, Eur Respir J source
- cites [273] Chalmers, 2014, The bronchiectasis severity index. An international derivation and validation study, Am J Respir Crit Care Med source
The Abstract and Discussion describe the BSI as a prognostic severity tool for non-CF bronchiectasis, derived and validated in cohorts spanning a wide range of disease severity. The Results identify low BMI and frequent exacerbations among its predictors. The paper does not address transplant timing or describe the FACED score, so those parts of the attributed claim are unsupported. (LLM, conf=0.86)
Experimental — accuracy not yet measured
- Method
The paper says inhaled cannabis must be stopped before lung transplant.
“Inhaled cannabis use must be ceased prior to lung transplant.(115–119)”
Quote in the paperNot yet classified1 of 5 sources checked- cites [115] 2017
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [116] Marks, 1996, Successfully treated invasive pulmonary aspergillosis associated with smoking marijuana in a renal transplant recipient, Transplantation source
- cites [117] Hamadeh, 1988, Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient, Chest source
- cites [118] Levi, 2019, Marijuana use in transplantation: a call for clarity, Clin Transplant source
- cites [119] Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol source
The Introduction says the paper addresses workplace cannabinoid testing, and the Conclusions discuss testing for workplace impairment. Searches for lung transplantation and pre-transplant cessation found no passage addressing whether inhaled cannabis must be stopped before a lung transplant. (LLM, conf=0.78)
Experimental — accuracy not yet measured
- Background
The paper says IPF has an untreated survival of about 3 to 5 years and that antifibrotics slow FVC decline and disease progression.
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
Quote in the paperNot yet classified2 of 3 sources checked- cites [191] King, 2014, A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis, New Eng J Med source
- cites [192] Richeldi, 2014, Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis, New Eng J Med source
The Abstract reports that nintedanib reduced FVC decline in patients with IPF, consistent with slower disease progression. The passages in our copy do not establish the claimed 3–5-year untreated survival, a benefit from pirfenidone, or efficacy specifically in both definite and probable UIP patterns. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [193] Raghu, 2017, Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria, Am J Respir Crit Care Med source
The Results (page not supplied) show that nintedanib reduced FVC decline in both diagnostic subgroups; the Discussion describes a similar treatment effect in patients with possible UIP and traction bronchiectasis. The cited paper does not establish the claimed 3–5-year untreated survival or an effect of pirfenidone in these subgroups. (LLM, conf=0.88)
Experimental — accuracy not yet measured
- Method
The paper says a full transplant evaluation should assess disease severity, anatomy, nutrition, frailty, comorbidities, psychosocial context, and health behaviors.
“A full evaluation includes assessment of lung disease severity, anatomy, nutritional status, degree of frailty, presence and severity of comorbidities, psychosocial circumstances, and health-related behaviors that impact recovery and long-term survival.”
Quote in the paperNot yet classified - Background
The paper frames lung transplant candidate selection around utility, justice, and respect for persons.
“The fundamental ethical principles of “utility”, “justice”, and “respect for persons” (see Table 1) must therefore, provide the framework for candidate selection and organ allocation systems.”
Quote in the paperNot yet classified0 of 2 sources checked- cites [5] Beauchamp, 2012
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites [6] Ethical Principles in the Allocation of Human Organs. Organ Procurement and Transplant Network. Accessed August 12, 2021. https://optn.transplant.hrsa.gov/resources/ethics/ethical-principles-in-the-allocation-of-human-organs/
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Background
The paper states that lung function decline should be tracked differently in ILD patients with emphysema because forced vital capacity can be misleading.
“In patients with concurrent emphysema, a decline in FVC is a less reliable parameter to detect progression of fibrosis, and other markers such as progression of disease on CT scan or DLCO, or development of secondary pulmonary hypertension, may be more useful.”
Quote in the paperNot yet classified - Background
The authors state that medical comorbidities, psychosocial factors, and rehabilitation potential must be considered when evaluating candidates.
“It is essential to account for medical comorbidities, psychosocial factors, and potential for rehabilitation in the evaluation of transplant candidates.”
Quote in the paperNot yet classified - Method
In areas with limited evidence, the committee used consensus statements that required more than 80% agreement.
“In areas where there was paucity of evidence, the statements reflect consensus reached by the committee with an a priori threshold of >80% agreement on consensus statements.”
Quote in the paperNot yet classified - Method
The consensus process used literature searches from early 2020 and included newer studies published after the 2014 document, but it did not repeat a full literature review.
“Literature searches performed in early 2020 reviewed all pertinent articles, focusing on newer peer reviewed research available since publication of the 2014 consensus document.(4) During review of the document additional pertinent newly published articles were included, but a comprehensive review of literature was not repeated.”
Quote in the paperNot yet classified0 of 1 sources checked- cites [4] Weill, 2015, A consensus document for the selection of lung transplant candidates: 2014–an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation, J Heart Lung Transplant source
- Background
The authors state that allocation decisions should prioritize survival benefit because lung transplantation uses a scarce resource.
“when making recommendations about allocating a scare resource, survival benefit is prioritized based on the ethical framework described in this document.”
Quote in the paperNot yet classified - Method
The document aims to guide referral, assessment, optimization, and listing of people who may receive a lung transplant.
“This document is intended to express a consensus of the membership of the International Society for Heart and Lung Transplantation (ISHLT) to provide guidance for timely referral, assessment, optimization, and listing of potential lung transplant candidates.”
Quote in the paperNot yet classified - Background
The document says candidate selection should maximize survival benefit for the individual and society.
“Our recommendations have the explicit goal of maximizing long-term survival in order to provide net survival gains for society as a whole.”
Quote in the paperNot yet classified - Background
The paper says nonadherence, dementia, and active substance use are among the few psychosocial contraindications treated as absolute.
“These include non-adherence to medical treatment, progressive cognitive impairment, and active substance use (Table 2).”
Quote in the paperNot yet classified - Background
The paper says COPD prognostic models are imprecise and that multidimensional models are better mortality predictors than single variables.
“Prognostic models that can be used to determine the appropriate timing of listing for lung transplant for COPD patients are inherently imprecise as survival is highly variable even among patients with advanced disease. In general, multidimensional models have proven to be more robust predictors of mortality than single parameters.”
Quote in the paperNot yet classified
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Active infections are generally contraindications for transplantation.
“Active infections are generally contraindications for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Infectious Disease Risk Factors section says B. cenocepacia infection may be considered an absolute contraindication at many centers. But it also says infection with multidrug-resistant organisms is no longer universally an absolute contraindication, and describes circumstances in which patients with other infections may receive a lung transplant. The source therefore supports concern about particular active infections, not the broad statement that active infections are generally contraindications. (LLM, conf=0.82)
Experimental — accuracy not yet measuredIn cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.
“In cases of CF and non-CF bronchiectasis, the colonization of resistant bacteria progresses, thereby increasing mortality after surgery.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Infectious Disease Risk Factors section associates B. cenocepacia with increased post-transplant mortality, and the Cystic Fibrosis section links resistant-organism colonization to decline or death before transplant. The copy does not establish that resistant-bacterial colonization progressively increases after surgery or that it increases post-transplant mortality across both CF and non-CF bronchiectasis. Page numbers were not available in the indexed passages. (LLM, conf=0.84)
Experimental — accuracy not yet measuredCOPD remains the most common indication for lung transplantation.
“Although COPD remains the most common indication for lung transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Disease Specific Considerations section discusses COPD as an indication for lung transplantation, and the Other Indications section says the document addresses some of the most common indications. Neither passage says COPD is the single most common indication or compares its frequency with other diagnoses; page numbers were not available in our copy. (LLM, conf=0.76)
Experimental — accuracy not yet measuredTransplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment.
“transplantation is possible despite infections with non-tuberculous mycobacteria, non-aspergillus molds, and Burkholderia cepacia complex if accompanied by appropriate treatment [3,26-28].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Infectious Disease Risk Factors sections support that these infections need not categorically rule out lung transplantation. But treatment alone is not presented as sufficient: the document calls for specialized-center management for M. abscessus and Burkholderia cepacia complex, and individualized candidacy decisions for non-aspergillus molds. Page numbers were not provided in our copy. (LLM, conf=0.83)
Experimental — accuracy not yet measuredThe BODE score is still the most important indicator, and along with FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension.
“the BODE score (body mass index, degree of airway obstruction, dyspnea, and exercise capacity score) is still the most important indicator, and along with it, FEV1 and the presence or absence of acute exacerbation determine whether transplantation is possible based on the presence or absence of evidence for pulmonary arterial hypertension (PAH), as summarized in Table 2 [3,42].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 and 2015 European Society of Cardiology/European Respiratory Society.
“The current consensus is based on 2 tools for referral and listing: the REVEAL Registry 2.2 (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management 2.0) and 2015 European Society of Cardiology/European Respiratory Society.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Pulmonary Arterial Hypertension section (page unavailable) identifies REVEAL 2.0 and the 2015 ESC/ERS model as the two most frequently used PAH risk-assessment models and uses them in discussing transplant referral. It does not call the score “REVEAL 2.2,” and it says additional clinical data must also be considered; the claim overstates their role as the two tools on which referral and listing are based. (LLM, conf=0.89)
Experimental — accuracy not yet measuredGroup 2, with decreased left ventricular function, is not an indication for transplantation.
“Group 2, with decreased left ventricular function, is not an indication for transplantation”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Heart Failure section says most centers will not perform lung transplantation in patients with a low left ventricular ejection fraction. It does not state that Group 2 pulmonary hypertension is categorically not an indication for transplantation; the Heart-lung transplant section also discusses options for candidates with cardiac disease. Page numbers were not available in our copy. (LLM, conf=0.86)
Experimental — accuracy not yet measuredIn the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.
“In the World Symposium of Pulmonary Hypertension classification of PAH, group 1 is the most common indication.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The “Indications for lung transplant in children” section (page unavailable) says idiopathic pulmonary arterial hypertension is the most common lung-transplant indication for children aged 1–5. It does not say that World Symposium group 1 is the most common indication generally, so the claim extends a narrower finding beyond the population and category stated in the paper. (LLM, conf=0.79)
Experimental — accuracy not yet measuredTransplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present.
“transplantation may be necessary if prostacyclin treatment is required for an appropriate intervention, there is accompanying liver or renal failure, or severe hemoptysis is present [3,59-62]”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Pulmonary Arterial Hypertension section (page unavailable) supports considering transplant for high-risk patients, including those with renal insufficiency, hepatic dysfunction, or hemoptysis. It does not say that needing prostacyclin treatment alone warrants transplantation: it discusses listing when advanced symptoms persist despite combination therapy with prostanoids. It also describes potentially reversible organ dysfunction in PAH, rather than liver or renal failure generally. (LLM, conf=0.87)
Experimental — accuracy not yet measuredIn 2021, the ISHLT published a new consensus document for selecting candidates for lung transplantation.
“In 2021, the International Society for Heart and Lung Transplantation (ISHLT) published a new consensus document for selecting candidates for lung transplantation [3].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
Group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.
“group 3 with PAH and accompanying pathological changes in the lung parenchyma can be considered for transplantation.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.
“The use of immunosuppressive drugs after transplantation may lead to poor control of infection and progression to sepsis.”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [3]
The Infectious Disease Risk Factors section discusses severe infections after lung transplantation, and the Hematologic Abnormalities section mentions maintenance immunosuppression after transplant (page numbers unavailable). Neither links immunosuppressive drugs to poor infection control or progression to sepsis; searches for those terms and the proposed causal link found no supporting passage in our copy. (LLM, conf=0.70)
Experimental — accuracy not yet measured
Citations
Cites
Principles of Biomedical Ethics
(2012) · Thieves of Virtue · doi:10.7551/mitpress/9079.003.0009 · Cited by 13,453
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,730
Acute Respiratory Distress Syndrome
Ards Definition Task Force (2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 8,987
2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv317 · Cited by 6,931
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A., Pinto Plata, V., & Cabral, H. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa021322 · Cited by 4,015
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Haemodynamic definitions and updated clinical classification of pulmonary hypertension
Simonneau, G., Montani, D., Celermajer, D. S., Denton, C. P., Gatzoulis, M. A., Krowka, M., Williams, P. G., & Souza, R. (2019) · European Respiratory Journal · doi:10.1183/13993003.01913-2018 · Cited by 3,813
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
Flaherty, K. R., Wells, A. U., Cottin, V., Devaraj, A., Walsh, S. L. F., Inoue, Y., Richeldi, L., Kolb, M., Tetzlaff, K., Stowasser, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908681 · Cited by 2,403
A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030287 · Cited by 2,071 · cited 2×
“…benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the time of…”
BackgroundLederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
(2006) · Surgery · doi:10.1016/s0039-6060(06)00616-7 · Cited by 1,642
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Weill, D., Benden, C., Corris, P. A., Dark, J. H., Davis, R. D., Keshavjee, S., Lederer, D. J., Mulligan, M. J., Patterson, G. A., Singer, L. G., et al. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.06.014 · Cited by 1,329 · cited 1×
“2,4 There has been no endorsement of an upper age limit as an absolute contraindication, but older individuals have worse long-term survival following lung transplant.”
BackgroundSelf-citationChambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
The bronchiectasis severity index. An international derivation and validation study
Chalmers, J. D., Goeminne, P., Aliberti, S., McDonnell, M. J., Lonni, S., Davidson, J., Poppelwell, L., Salih, W., Pesci, A., Dupont, L. J., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1575oc · Cited by 1,093
Orens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Self-citationPrediction of mortality in patients with cystic fibrosis
Kerem, E., Reisman, J., Corey, M., Canny, G. J., & Levison, H. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204303261804 · Cited by 993
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846 · cited 1×
“289,290 Furthermore, specific clinical scenarios known to equate to a high-risk profile need to be considered.”
BackgroundRisk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Pulmonary hypertension in chronic lung disease and hypoxia
Nathan, S. D., Barbera, J. A., Gaine, S. P., Harari, S., Martinez, F. J., Olschewski, H., Olsson, K. M., Peacock, A. J., Pepke-Zaba, J., Provencher, S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01914-2018 · Cited by 757
Spectrum of fibrotic lung diseases
Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2005230 · Cited by 736
Self-citationHoeper, M. M., Kramer, T., Pan, Z., Eichstaedt, C. A., Spiesshoefer, J., Benjamin, N., Olsson, K. M., Meyer, K., Vizza, C. D., Vonk-Noordegraaf, A., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.00740-2017 · Cited by 660 · cited 1×
“288 Finally, this approach, similar to the RSS, still needs to be validated prospectively.”
MethodCottin, V., Hirani, N., Hotchkin, D. L., Nambiar, A. M., Ogura, T., Otaola, M., Skowasch, D., Park, J. S., Poonyagariyagorn, H. K., Wuyts, W. A., et al. (2018) · European Respiratory Review · doi:10.1183/16000617.0076-2018 · Cited by 656
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Benza, R. L., Gomberg-Maitland, M., Elliott, C. G., Farber, H. W., Foreman, A. J., Frost, A. E., McGoon, M. D., Pasta, D. J., Selej, M., Burger, C. D., et al. (2019) · Chest · doi:10.1016/j.chest.2019.02.004 · Cited by 643
Rossano, J. W., Cherikh, W. S., Chambers, D. C., Goldfarb, S., Hayes, D., Khush, K. K., Kucheryavaya, A. Y., Toll, A. E., Levvey, B. J., Meiser, B., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.018 · Cited by 637
Rosenzweig, E. B., Abman, S. H., Adatia, I., et al. (2018) · European Respiratory Journal · doi:10.1183/13993003.01916-2018 · Cited by 629 · cited 1×
“136,137 Children with PAH in the high-risk category and on optimal therapy without improvement should be listed for lung transplantation.”
BackgroundMaher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis
Johnson, S. R., Cordier, J. F., Lazor, R., Cottin, V., Costabel, U., Harari, S., Reynaud-Gaubert, M., Boehler, A., Brauner, M., Popper, H., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00076209 · Cited by 590
Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30036-9 · Cited by 589
International guidelines for the selection of lung transplant candidates
Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · Transplantation · doi:10.1097/00007890-199810150-00033 · Cited by 562
Self-citationPredicting Survival Across Chronic Interstitial Lung Disease
Ryerson, C. J., Vittinghoff, E., Ley, B., Lee, J. S., Mooney, J. J., Jones, K. D., Elicker, B. M., Wolters, P. J., Koth, L. L., King, T. E., et al. (2014) · Chest · doi:10.1378/chest.13-1474 · Cited by 558
Pediatric Pulmonary Hypertension
Ivy, D. D., Abman, S. H., Barst, R. J., Berger, R. M. F., Bonnet, D., Fleming, T. R., Haworth, S. G., Raj, J. U., Rosenzweig, E. B., Schulze‐Neick, I., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.028 · Cited by 543
Prognostic Factors in COPD Patients Receiving Long-term Oxygen Therapy
Oswald–Mammosser, M., Weitzenblum, E., Quoix, É., Moser, G., Chaouat, A., Charpentier, C., & Kessler, R. (1995) · CHEST Journal · doi:10.1378/chest.107.5.1193 · Cited by 516
Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score
Martínez-García, M. Á., de Gracia, J., Vendrell Relat, M., Girón, R.-M., Máiz Carro, L., de la Rosa Carrillo, D., & Olveira, C. (2014) · European Respiratory Journal · doi:10.1183/09031936.00026313 · Cited by 503
Chambers, D. C., Cherikh, W. S., Goldfarb, S. B., Hayes, D., Kucheryavaya, A. Y., Toll, A. E., Khush, K. K., Levvey, B. J., Meiser, B., Rossano, J. W., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.07.020 · Cited by 498 · cited 1×
“153,270 Finally, the risk of colorectal cancer is increased in CF compared to age-matched controls, and transplant programs should screen CF candidates with colonoscopy beginning at age 40 years based on the 2017 CF Foundation Guidelines.”
BackgroundHansmann, G., Köestenberger, M., Alastalo, T.-P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.06.022 · Cited by 444
Predictors of Mortality in Patients with Emphysema and Severe Airflow Obstruction
Martínez, F. J., Foster, G. L., Curtis, J. L., Criner, G. J., Weinmann, G. G., Fishman, A. P., DeCamp, M. M., Benditt, J. O., Sciurba, F. C., Make, B. J., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1677oc · Cited by 441
Criner, G. J., Sue, R., Wright, S., Dransfield, M., Rivas-Perez, H., Wiese, T., Sciurba, F. C., Shah, P. L., Wahidi, M. M., de Oliveira, H. G., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201803-0590oc · Cited by 428
Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis
Esther, C. R., Esserman, D. A., Gilligan, P., Kerr, A., & Noone, P. G. (2010) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2009.12.001 · Cited by 410
Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive
Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard, H. R., & Garcia, C. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.00308-2016 · Cited by 400
Kemp, S. V., Slebos, D., Kirk, A. J. B., Kornaszewska, M., Carron, K., Ek, L., Broman, G., Hillerdal, G., Mal, H., Pison, C. M., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201707-1327oc · Cited by 397
George, P. M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F. J., Molyneaux, P. L., Renzoni, E. A., Richeldi, L., Tomassetti, S., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30355-6 · Cited by 349
Dew, M. A., Rosenberger, E. M., Myaskovsky, L., DiMartini, A. F., DeVito Dabbs, A. J., Posluszny, D. M., Steel, J., Switzer, G. E., Shellmer, D. A., & Greenhouse, J. B. (2015) · Transplantation · doi:10.1097/tp.0000000000000901 · Cited by 304
Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient Registry
Kerem, E., Viviani, L., Zolin, A., MacNeill, S., Hatziagorou, E., Ellemunter, H., Drevinek, P., Gulmans, V., Krivec, U., & Olesen, H. (2014) · European Respiratory Journal · doi:10.1183/09031936.00166412 · Cited by 296 · cited 1×
“…mycobacteria ( M. abscessus in particular) have been shown to increase the rate of lung function decline or death without transplant in advanced CF. 245,247,254,258,262 Implications of B. cenoce-pacia, M. abscessus , or L. prolificans are described above (infectious disease risk factors).”
BackgroundThe natural history of progressive fibrosing interstitial lung diseases
Brown, K. K., Martinez, F. J., Walsh, S. L. F., Thannickal, V. J., Prasse, A., Schlenker-Herceg, R., Goeldner, R.-G., Clerisme-Beaty, E., Tetzlaff, K., Cottin, V., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00085-2020 · Cited by 293
Moghadam‐Kia, S., Oddis, C. V., Sato, S., et al. (2015) · Arthritis Care & Research · doi:10.1002/acr.22728 · Cited by 279
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
de Boer, K., Vandemheen, K. L., Tullis, E., Doucette, S., Fergusson, D., Freitag, A., Paterson, N., Jackson, M., Lougheed, M. D., Kumar, V., et al. (2011) · Thorax · doi:10.1136/thx.2011.161117 · Cited by 271
Maher, T. M., Oballa, E., Simpson, J. K., Porte, J., Habgood, A., Fahy, W. A., Flynn, A., Molyneaux, P. L., Braybrooke, R., Divyateja, H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30430-7 · Cited by 271
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality
Mayer-Hamblett, N., Rosenfeld, M., Emerson, J., Goss, C. H., & Aitken, M. L. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200202-087oc · Cited by 269
Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management
Wijsenbeek, M. S., Kreuter, M., Olson, A. L., Fischer, A., Bendstrup, E. M., Wells, C. D., Denton, C. P., Mounir, B., Zouad-Lejour, L., Quaresma, M., et al. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1647040 · Cited by 268
Self-citationBelli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251
The impact of cognitive function on medication management: Three studies.
Stilley, C. S., Bender, C. M., Dunbar-Jacob, J., Sereika, S., & Ryan, C. M. (2010) · Health Psychology · doi:10.1037/a0016940 · Cited by 248
Predictors of mortality in pulmonary sarcoidosis
Kirkil, G., Lower, E. E., & Baughman, R. P. (2018) · Chest · doi:10.1016/j.chest.2017.07.008 · Cited by 243
Scott, M. K. D., Quinn, K., Li, Q., Carroll, R. J., Warsinske, H., Vallania, F., Chen, S., Carns, M. A., Aren, K., Sun, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30508-3 · Cited by 240
Ramos, K. J., Smith, P. J., McKone, E. F., Pilewski, J. M., Lucy, A., Hempstead, S. E., Tallarico, E., Faro, A., Rosenbluth, D. B., Gray, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.03.002 · Cited by 227 · cited 2×
“134,261 These goals will continue to be important even in the era of highly effective CFTR modulators, particularly in patients who are ineligible for, cannot tolerate, or do not respond to such therapy, or if adverse long-term clinical effects arise.”
BackgroundSelf-citationFrailty phenotypes, disability, and outcomes in adult candidates for lung transplantation
Singer, J. P., Diamond, J. M., Gries, C. J., McDonnough, J., Blanc, P. D., Shah, R., Dean, M. Y., Hersh, B., Wolters, P. J., Tokman, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1150oc · Cited by 224 · cited 1×
“49,50 51-53 However, frailty in lung transplant candidates is often attributable to advanced lung disease and may improve following transplant.”
BackgroundSelf-citationProgressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)
Nasser, M., Larrieu, S., Si-Mohamed, S. A., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.02718-2020 · Cited by 220
Hoeper, M. M., Benza, R. L., Corris, P., de Perrot, M., Fadel, E., Keogh, A. M., Kühn, C., Savale, L., & Klepetko, W. (2019) · European Respiratory Journal · doi:10.1183/13993003.01906-2018 · Cited by 216
Massive hemoptysis in cystic fibrosis
Flume, P. A., Yankaskas, J. R., Ebeling, M., Hulsey, T., & Clark, L. L. (2005) · Chest · doi:10.1378/chest.128.2.729 · Cited by 215
Obesity and underweight are associated with an increased risk of death after lung transplantation
Lederer, D. J., Wilt, J. S., D'Ovidio, F., Bacchetta, M. D., Shah, L., Ravichandran, S., Lenoir, J., Klein, B., Sonett, J. R., & Arcasoy, S. M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0425oc · Cited by 198
Self-citationPredicting outcomes in idiopathic pulmonary fibrosis using automated computed tomographic analysis
Jacob, J., Bartholmai, B. J., Rajagopalan, S., van Moorsel, C. H. M., van Es, H. W., van Beek, F. T., Struik, M. H. L., Kokosi, M., Egashira, R., Brun, A. L., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201711-2174oc · Cited by 198
Bellou, V., Belbasis, L., Konstantinidis, A. K., Tzoulaki, I., & Evangelou, E. (2019) · BMJ · doi:10.1136/bmj.l5358 · Cited by 197
Cystic fibrosis colorectal cancer screening consensus recommendations
Hadjiliadis, D., Khoruts, A., Zauber, A. G., Hempstead, S. E., Maisonneuve, P., Lowenfels, A. B., Braid, A. L., Cullina, J., Daggett, A., Fink, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.12.012 · Cited by 195
Lung disease as a determinant of cognitive decline and dementia
Dodd, J. W. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0116-3 · Cited by 192
Dew, M. A., DiMartini, A. F., Dobbels, F., Grady, K. L., Jowsey‐Gregoire, S. G., Kaan, A., Kendall, K., Young, Q., Abbey, S. E., Butt, Z. A., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.03.005 · Cited by 192 · cited 3×
“86 Despite wide recognition of the importance of psychosocial functioning for favorable lung transplant outcomes, few psychosocial contraindications are considered absolute.”
BackgroundSelf-citationCriner, G. J., Delage, A., Voelker, K., Hogarth, D. K., Majid, A., Zgoda, M., Lazarus, D. R., Casal, R., Benzaquen, S. B., Holladay, R. C., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201902-0383oc · Cited by 182 · cited 1×
“181-183 Survival benefit has been demonstrated in a select group of patients with upper lobe predominant emphysema and low exercise capacity who undergo surgical LVR. 183 184-187 Prior LVR surgery can lead to formation of pleural adhesions, which can pose technical challenges to the surgeon at the…”
BackgroundRisk factors for death of patients with cystic fibrosis awaiting lung transplantation
Belkin, R. A., Henig, N. R., Singer, L. G., Chaparro, C., Rubenstein, R. C., Xie, S. X., Yee, J. Y., Kotloff, R. M., Lipson, D. A., & Bunin, G. R. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200410-1369oc · Cited by 180
Self-citationEffect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Newton, C. A., Oldham, J. M., Ley, B., Anand, V. C., Adegunsoye, A., Liu, G. Y., Batra, K., Torrealba, J. R., Kozlitina, J., Glazer, C. S., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01641-2018 · Cited by 180
Alexander, B. D., Petzold, E. W., Reller, L. B., Palmer, S. M., Davis, R. D., Woods, C. W., & LiPuma, J. J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02186.x · Cited by 177
Impact of Burkholderia Infection on Lung Transplantation in Cystic Fibrosis
Murray, S., Charbeneau, J., Marshall, B. C., & LiPuma, J. J. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200712-1834oc · Cited by 177 · cited 1×
“cenocepacia has been associated with post-transplant infections and increased mortality especially within the first 6-12 months.(72,73) While it may be considered an absolute contraindication at many centers, patients may be candidates at specialized centers that have attained satisfactory outcomes with protocols impl…”
BackgroundHayes, D., Cherikh, W. S., Chambers, D. C., Harhay, M. O., Khush, K. K., Lehman, R. R., Meiser, B., Rossano, J. W., Hsich, E., Potena, L., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.003 · Cited by 168
Risk of death in cystic fibrosis patients with severely compromised lung function
Milla, C. E., & Warwick, W. J. (1998) · Chest · doi:10.1378/chest.113.5.1230 · Cited by 167
Pneumothorax in cystic fibrosis
Flume, P. A., Strange, C., Ye, X., Ebeling, M., Hulsey, T., & Clark, L. L. (2005) · Chest · doi:10.1378/chest.128.2.720 · Cited by 164
Hoetzenecker, K., Donahoe, L., Yeung, J. C., Azad, S., Fan, E., Ferguson, N. D., Del Sorbo, L., de Perrot, M., Pierre, A., Yasufuku, K., et al. (2018) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2017.09.161 · Cited by 164 · cited 2×
“143,144 Indications for ECLS include hypercapnic respiratory failure, hypoxic respiratory failure, and right ventricular failure.”
BackgroundSelf-citationAl-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16318 · Cited by 163 · cited 2×
“Malignancy with high risk of recurrence or death is an absolute contraindication, but it is increasingly acknowledged in the context of lung transplant that not all neoplastic diseases are equal.(13,14) Certain malignancies may not be significantly affected by immunosuppression and some may be managed post-transplant…”
BackgroundSurvival in Sensitized Lung Transplant Recipients With Perioperative Desensitization
Tinckam, K. J., Keshavjee, S., Chaparro, C., Barth, D., Azad, S., Binnie, M., Chow, C. W., de Perrot, M., Pierre, A. F., Waddell, T. K., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13076 · Cited by 161 · cited 1×
“However, some centers describe successful lung transplantation despite positive cross match.(62,63) Cut-off levels for organ acceptance and the optimal methods for detection of functional donor specific antibodies have not been determined.”
BackgroundSelf-citationImpact of the lung allocation score on lung transplantation for pulmonary arterial hypertension
Chen, H., Shiboski, S. C., Golden, J. A., Gould, M. K., Hays, S. R., Hoopes, C. W., & De Marco, T. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200810-1603oc · Cited by 161
OPTN/SRTR 2019 annual data report: lung
Valapour, M., Lehr, C. J., Skeans, M. A., Smith, J. M., Miller, E., Goff, R., Foutz, J., Israni, A. K., Snyder, J. J., & Kasiske, B. L. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16495 · Cited by 161 · cited 1×
“8 With increasing experience in older recipients, several studies have shown that carefully selected older recipients may have the same short-term survival as younger recipients.”
BackgroundSelf-citationFadel, É., Mercier, O. M., Mussot, S., Leroy-Ladurie, F., Cerrina, J., Chapelier, A. R., Simonneau, G., & Dartevelle, P. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.02.039 · Cited by 156 · cited 1×
“156-159 Similarly, patients with advanced lung disease and cardiac pathology amenable to surgical repair may be candidates for lung transplant concurrent with the appropriate correc-tive cardiac procedure.”
BackgroundFundoplication after lung transplantation prevents the allograft dysfunction associated with reflux
Hartwig, M. G., Anderson, D. J., Onaitis, M. W., Reddy, S., Snyder, L. D., Lin, S. S., & Davis, R. D. (2011) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2011.04.035 · Cited by 155 · cited 2×
“38,39 40-42 In one study, when stratified by degree of obesity, the risk of mortality was increased for patients with a BMI > 35 and not in those with BMI 30-34.9.”
BackgroundInfluentialSelf-citationSato, S., Masui, K., Nishina, N., et al. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key060 · Cited by 155
Fatal aspergillosis associated with smoking contaminated marijuana, in a marrow transplant recipient
Hamadeh, R., Ardehali, A., Locksley, R. M., & York, M. K. (1988) · Chest · doi:10.1378/chest.94.2.432 · Cited by 151
Wickerson, L. M., Rozenberg, D., Janaudis‐Ferreira, T., Deliva, R. D., Lo, V., Beauchamp, G., Helm, D., Gottesman, C., Mendes, P. L., Vieira, L., et al. (2016) · World Journal of Transplantation · doi:10.5500/wjt.v6.i3.517 · Cited by 143 · cited 1×
“Pre- and post-transplant pulmonary rehabilitation should be recommended for transplant candidates and recipients.(57,58) Human Leucocyte Antigen (HLA) Antibodies: Elevated HLA specific antibodies detected in peripheral blood may make finding a compatible donor difficult and may predict poor outcomes.”
BackgroundBody composition and mortality after adult lung transplantation in the United States
Singer, J. P., Peterson, E. R., Snyder, M. E., Katz, P. P., Golden, J. A., D’Ovidio, F., Bacchetta, M., Sonett, J. R., Kukreja, J., Shah, L., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0973oc · Cited by 133 · cited 2×
“42 These patients should be encouraged to lose weight as the magnitude of pre-trans-plant weight loss is directly correlated with improvements in post-transplant survival for candidates who are not underweight.”
BackgroundInfluentialSelf-citationFrailty phenotypes and mortality after lung transplantation: a prospective cohort study
Singer, J. P., Diamond, J. M., Anderson, M. R., Katz, P. P., Covinsky, K., Oyster, M., Blue, T., Soong, A., Kalman, L., Shrestha, P., et al. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14873 · Cited by 133
Self-citationInoue, Y., Kaner, R. J., Guiot, J., Maher, T. M., Tomassetti, S., Moiseev, S., Kuwana, M., & Brown, K. K. (2020) · Chest · doi:10.1016/j.chest.2020.03.037 · Cited by 133
Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.02.005 · Cited by 132
Holzmann, D., Speich, R., Kaufmann, T., Laube, I., Russi, E. W., Simmen, D., Weder, W., & Boehler, A. (2004) · Transplantation · doi:10.1097/01.tp.0000100467.74330.49 · Cited by 127
Lung transplantation: indications and contraindications
Weill, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.06.141 · Cited by 127 · cited 1×
“163 In addition, one study has suggested there may be no survival advantage with lung-liver transplant when compared to matched single-organ lung transplant recipients with an equivalent degree of liver dysfunction, suggesting a need for more precise criteria to determine optimal lung-liver…”
BackgroundSelf-citationTherapies for refractory hypoxemia in acute respiratory distress syndrome
Pipeling, M. R., & Fan, E. (2010) · JAMA · doi:10.1001/jama.2010.1752 · Cited by 126
Spectrum of Fibrotic Lung Diseases
Karim, F., van Laar, J. A. M., & van Hagen, M. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031135 · Cited by 126
Twenty-year experience with extracorporeal life support as bridge to lung transplantation
Benazzo, A., Schwarz, S., Frommlet, F., Schweiger, T., Jaksch, P., Schellongowski, P., Staudinger, T., Klepetko, W., Lang, G., Hoetzenecker, K., et al. (2019) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2019.02.048 · Cited by 126 · cited 2×
“143,144 Indications for ECLS include hypercapnic respiratory failure, hypoxic respiratory failure, and right ventricular failure.”
BackgroundMarks, W. H., Florence, L., Lieberman, J., Chapman, P., Howard, D., Roberts, P., & Perkinson, D. (1996) · Transplantation · doi:10.1097/00007890-199606270-00018 · Cited by 125
Adherence to the Medical Regimen During the First Two Years After Lung Transplantation
Dew, M. A., DiMartini, A. F., De Vito Dabbs, A., Zomak, R., De Geest, S., Dobbels, F., Myaskovsky, L., Switzer, G. E., Unruh, M., Steel, J. L., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e318160135f · Cited by 124
Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
Verleden, S. E., Todd, J. L., Sato, M., Palmer, S. M., Martinu, T., Pavlisko, E. N., Vos, R., Neyrinck, A., Van Raemdonck, D., Saito, T., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13281 · Cited by 123 · cited 1×
“1,139,140 Pneumothorax / Pleurodesis : When possible, management of a pneumothorax in a patient who may be a potential lung transplant candidate should be discussed with a transplant center.”
BackgroundThabut, G., Ravaud, P., Christie, J. D., Castier, Y., Fournier, M., Mal, H., Lesèche, G., & Porcher, R. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200708-1283oc · Cited by 122
Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema
Martínez, F. J., Han, M. K., Andrei, A., Wise, R. A., Murray, S., Curtis, J. L., Sternberg, A., Criner, G. J., Gay, S. E., Reilly, J. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1383oc · Cited by 120 · cited 1×
“175,177,178 While DLCO has not been shown to be an independent predictor of mortality in COPD, a low DLCO has been associated with increased COPD symptoms, reduced exercise performance, and severe exacerbation risk, and thus, also may prompt consideration of referral.”
BackgroundBehr, J., Neuser, P., Prasse, A., et al. (2017) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0462-y · Cited by 120
Pulmonary rehabilitation in lung transplant candidates
Li, M. M., Mathur, S., Chowdhury, N., Helm, D., & Singer, L. G. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.04.002 · Cited by 116 · cited 1×
“57,58 59-61 However, some centers describe successful lung transplantation despite positive cross match.”
BackgroundWhen to consider lung transplantation for COVID-19
Cypel, M., & Keshavjee, S. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30393-3 · Cited by 116
Self-citationKillian, M., Schuman, D. L., Mayersohn, G. S., & Triplett, K. N. (2018) · Pediatric Transplantation · doi:10.1111/petr.13188 · Cited by 113
de Perrot, M. E., Granton, J. T., McRae, K. M., Pierre, A. F., Singer, L. G., Waddell, T. K., & Keshavjee, S. H. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.08.055 · Cited by 111
de Perrot, M., Chernenko, S., Waddell, T. K., Shargall, Y., Pierre, A. F., Hutcheon, M., & Keshavjee, S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.188 · Cited by 109
Lobo, L. J., Chang, L. C., Esther, C. R., Gilligan, P. H., Tulu, Z., & Noone, P. G. (2013) · Clinical Transplantation · doi:10.1111/ctr.12140 · Cited by 108 · cited 1×
“64,65 66-69 Thus, patients with M. abscessus should be managed at centers with expertise and protocols for managing this infection.”
BackgroundThe US experience with lung transplantation for pulmonary lymphangioleiomyomatosis
Kpodonu, J., Massad, M. G., Chaer, R. A., Caines, A., Evans, A., Snow, N. J., & Geha, A. S. (2005) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.09.013 · Cited by 106
The efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis
Ando, K., Kurihara, M., Kataoka, H., Ueyama, M., Togo, S., Sato, T., Doi, T., Iwakami, S.-I., Takahashi, K., Seyama, K., et al. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.03.002 · Cited by 106
Date, H., Sato, M., Aoyama, A., Yamada, T., Mizota, T., Kinoshita, H., Handa, T., Tanizawa, K., Chin, K., Minakata, K., et al. (2014) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezu350 · Cited by 106
Gastroesophageal reflux in bronchiolitis obliterans syndrome: a new perspective
King, B. J., Iyer, H., Leidi, A. A., & Carby, M. R. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2009.05.040 · Cited by 105 · cited 1×
“32,33 Anti-reflux surgery pre-transplant and early post-transplant has been associated with a decrease in the development of early allograft dysfunction.”
BackgroundJackson, A., Cropper, J., Pye, R., Junius, F., Malouf, M., & Glanville, A. (2008) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2007.12.006 · Cited by 105
Self-citationMartin, C., Hamard, C., Kanaan, R., Boussaud, V., Grenet, D., Abély, M., Hubert, D., Munck, À., Lemonnier, L., & Burgel, P. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.09.002 · Cited by 103 · cited 1×
“134,261 These goals will continue to be important even in the era of highly effective CFTR modulators, particularly in patients who are ineligible for, cannot tolerate, or do not respond to such therapy, or if adverse long-term clinical effects arise.”
BackgroundRecurrence of bronchioloalveolar carcinoma in transplanted lungs
Garver, R. I., Zorn, G. L., Wu, X., McGiffin, D. C., Young, K. R., & Pinkard, N. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904083401403 · Cited by 102
Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation
Verleden, S. E., Vanaudenaerde, B. M., Emonds, M., Raemdonck, D. E. V., Neyrinck, A., Verleden, G. M., & Vos, R. (2017) · European Respiratory Journal · doi:10.1183/13993003.01248-2017 · Cited by 100
Diffusing Capacity of Carbon Monoxide in Assessment of COPD
Balasubramanian, A., MacIntyre, N. R., Henderson, R. J., Jensen, R. L., Kinney, G., Stringer, W. W., Hersh, C. P., Bowler, R. P., Casaburi, R., Han, M. K., et al. (2019) · Chest · doi:10.1016/j.chest.2019.06.035 · Cited by 100 · cited 1×
“179,180 The patient’s perception of an unacceptably poor quality of life may also be a consideration, albeit not the principal driver for referral, given the significant symptomatic benefits that transplant offers this patient population even in the face of an uncertain survival benefit.”
BackgroundLung transplantation for lymphangioleiomyomatosis: the European experience
Benden, C., Rea, F., Behr, J., Corris, P. A., Reynaud-Gaubert, M., Stern, M., Speich, R., & Boehler, A. (2009) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2008.09.014 · Cited by 99
Launay, D., Humbert, M., Berezne, A., Cottin, V., Allanore, Y., Couderc, L.-J., Bletry, O., Yaici, A., Hatron, P.-Y., Mouthon, L., et al. (2011) · Chest · doi:10.1378/chest.10-2473 · Cited by 99
Psychiatric predictors of long-term transplant-related outcomes in lung transplant recipients
Rosenberger, E. M., DiMartini, A. F., DeVito Dabbs, A. J., Bermudez, C. A., Pilewski, J. M., Toyoda, Y., & Dew, M. A. (2016) · Transplantation · doi:10.1097/tp.0000000000000824 · Cited by 97
Raghu, G., Richeldi, L., Jagerschmidt, A., Martin, V., Subramaniam, A., Ozoux, M., Espéret, C., & Soubrane, C. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1083 · Cited by 96
Ramos, K. J., Quon, B. S., Heltshe, S. L., Mayer-Hamblett, N., Lease, E. D., Aitken, M. L., Weiss, N. S., & Goss, C. H. (2017) · Chest · doi:10.1016/j.chest.2017.01.019 · Cited by 95 · cited 2×
“Special considerations in cystic fibrosis: Several comorbidities should be considered when evaluating candidates with CF. Infection or colonization with multi-drug resistant organisms including Burkholderia cepacia complex, Pseudomonas aeruginosa , and nontuberculous mycobacteria ( M. abscessus in particular) have been…”
BackgroundSelf-citationPulmonary veno-occlusive disease: recent progress and current challenges
Montani, D., O’Callaghan, D. S., Savale, L., Jaïs, X., Yaïci, A., Maitre, S., Dorfmuller, P., Sitbon, O., Simonneau, G., & Humbert, M. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.014 · Cited by 94
Psychosocial Predictors of Mortality Following Lung Transplantation
Smith, P. J., Blumenthal, J. A., Trulock, E. P., Freedland, K. E., Carney, R. M., Davis, R. D., Hoffman, B. M., & Palmer, S. M. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13447 · Cited by 93
Self-citationCommunity preferences for the allocation of solid organs for transplantation: a systematic review
Tong, A., Howard, K., Jan, S., Cass, A., Rose, J., Chadban, S., Allen, R. D., & Craig, J. C. (2010) · Transplantation · doi:10.1097/tp.0b013e3181cf1ee1 · Cited by 92
Vital, D., Hofer, M., Benden, C., Holzmann, D., & Boehler, A. (2013) · Respiration · doi:10.1159/000339627 · Cited by 91 · cited 1×
“263,264 264-267 Non-infectious comorbidities include malnutrition, which is common in CF patients approaching transplant and represents a potentially modifiable risk factor.”
BackgroundFrost, A. E., Badesch, D. B., Miller, D. P., Benza, R. L., Meltzer, L. A., & McGoon, M. D. (2013) · Chest · doi:10.1378/chest.12-3023 · Cited by 90
Singh, N., Varghese, J., England, B. R., Solomon, J. J., Michaud, K., Mikuls, T. R., Healy, H. S., Kimpston, E. M., & Schweizer, M. L. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.005 · Cited by 90
Acuña, S. A., Huang, J. W., Daly, C., Shah, P. S., Kim, S. J., & Baxter, N. N. (2016) · Transplantation · doi:10.1097/tp.0000000000001192 · Cited by 89 · cited 1×
“Transplant centers should work closely with oncology specialists to evaluate each patient with a history of cancer to determine the stagespecific risk of recurrence or progression, which may be higher in the setting of immunosuppression, and to determine the necessary cancer-free period prior to listing.(15,16) Renal…”
BackgroundLung transplantation for lymphangioleiomyomatosis: the French experience
Reynaud-Gaubert, M., Mornex, J.-F., Mal, H., Treilhaud, M., Dromer, C., Quétant, S., Leroy-Ladurie, F., Guillemain, R., Philit, F., Dauriat, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c15df · Cited by 87
on behalf of the IPF-PRO™ Registry investigators, Snyder, L. D., Neely, M. L., Hellkamp, A. S., O'Brien, E. C., de Andrade, J. A., Conoscenti, C., Leonard, T. B., Bender, S. D., Gulati, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1043-9 · Cited by 87
Al-Adra, D. P., Hammel, L., Roberts, J., Woodle, E. S., Levine, D., Mandelbrot, D., Verna, E., Locke, J., D’Cunha, J., Farr, M., et al. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16324 · Cited by 87 · cited 2×
“Malignancy with high risk of recurrence or death is an absolute contraindication, but it is increasingly acknowledged in the context of lung transplant that not all neoplastic diseases are equal.(13,14) Certain malignancies may not be significantly affected by immunosuppression and some may be managed post-transplant…”
BackgroundOutcomes in systemic sclerosis-related lung disease after lung transplantation
Sottile, P. D., Iturbe, D., Katsumoto, T. R., Connolly, M. K., Collard, H. R., Leard, L. A., Hays, S., Golden, J. A., Hoopes, C., Kukreja, J., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182845f23 · Cited by 85 · cited 1×
“36,37 Hematologic abnormalities : Thrombocytopenia, leukopenia, or anemia may contribute to peri-operative complications and may limit use of optimal maintenance immunosuppression and necessary antimicrobial prophylaxis following lung transplant.”
BackgroundSelf-citationSmith, J. D., Ibrahim, M. W., Newell, H., Danskine, A. J., Soresi, S., Burke, M. M., Rose, M. L., & Carby, M. (2014) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.02.033 · Cited by 85 · cited 1×
“57,58 59-61 However, some centers describe successful lung transplantation despite positive cross match.”
BackgroundYoung, A., Vummidi, D., Visovatti, S., Homer, K., Wilhalme, H., White, E. S., Flaherty, K., McLaughlin, V., & Khanna, D. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40862 · Cited by 85
Psychiatric disorders as risk factors for adverse medical outcomes after solid organ transplantation
Rosenberger, E. M., Dew, M. A., Crone, C., & DiMartini, A. F. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283510928 · Cited by 83
Effects of Sinus Surgery on lung Transplantation Outcomes in Cystic Fibrosis
Leung, M., Rachakonda, L. P., Weill, D., & Hwang, P. H. (2008) · American Journal of Rhinology · doi:10.2500/ajr.2008.22.3146 · Cited by 83
Self-citationLung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene Variants
Swaminathan, A. C., Neely, M. L., Frankel, C. W., Kelly, F. L., Petrovski, S., Durheim, M. T., Bush, E., Snyder, L. D., Goldstein, D. B., Todd, J. L., et al. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.03.030 · Cited by 83 · cited 1×
“38,39 40-42 In one study, when stratified by degree of obesity, the risk of mortality was increased for patients with a BMI > 35 and not in those with BMI 30-34.9.”
BackgroundInfluentialUpala, S., Panichsillapakit, T., Wijarnpreecha, K., Jaruvongvanich, V., & Sanguankeo, A. (2016) · Transplant International · doi:10.1111/tri.12721 · Cited by 81
Miele, C. H., Schwab, K., Saggar, R., Duffy, E., Elashoff, D., Tseng, C.-H., Weigt, S., Charan, D., Abtin, F., Johannes, J., et al. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201512-806oc · Cited by 81 · cited 1×
“36,37 Hematologic abnormalities : Thrombocytopenia, leukopenia, or anemia may contribute to peri-operative complications and may limit use of optimal maintenance immunosuppression and necessary antimicrobial prophylaxis following lung transplant.”
BackgroundTorrisi, S. E., Ley, B., Kreuter, M., Wijsenbeek, M., Vittinghoff, E., Collard, H. R., & Vancheri, C. (2019) · European Respiratory Journal · doi:10.1183/13993003.01587-2018 · Cited by 79
Self-citationChoong, C. K. C., Sweet, S. C., Guthrie, T. J., Mendeloff, E. N., Haddad, F. J., Schuler, P., de la Morena, M., & Huddleston, C. B. (2005) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2004.07.058 · Cited by 77
Pulmonary hypertension in cystic fibrosis with advanced lung disease
Hayes, D., Tobias, J. D., Mansour, H. M., Kirkby, S., McCoy, K. S., Daniels, C. J., & Whitson, B. A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201407-1382oc · Cited by 77
Lung transplantation for lymphangioleiomyomatosis
Pechet, T. T., Meyers, B. F., Guthrie, T. J., Battafarano, R. J., Trulock, E. P., Cooper, J. D., & Patterson, G. A. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(03)00195-5 · Cited by 77
Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease
Morisset, J., Vittinghoff, E., Elicker, B. M., Hu, X., Le, S., Ryu, J. H., Jones, K. D., Haemel, A., Golden, J. A., Boin, F., et al. (2017) · Chest · doi:10.1016/j.chest.2017.06.009 · Cited by 77
van Beers, M., Janssen, D. J. A., Gosker, H. R., & Schols, A. M. W. J. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1533405 · Cited by 77
Qvist, T., Pressler, T., Thomsen, V. O., Skov, M., Iversen, M., & Katzenstein, T. L. (2013) · Transplantation Proceedings · doi:10.1016/j.transproceed.2012.02.035 · Cited by 76
Benza, R. L., Miller, D. P., Frost, A., Barst, R. J., Krichman, A. M., & McGoon, M. D. (2010) · Transplantation · doi:10.1097/tp.0b013e3181e49b83 · Cited by 75
Courtwright, A. M., El-Chemaly, S., Dellaripa, P. F., & Goldberg, H. J. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.12.013 · Cited by 73 · cited 1×
“29,30 Screening for extra-pulmonary systemic disease in collaboration with a multidisciplinary team, including rheumatologists, gastroenterologists, and neph-rologists, is essential in these candidates as cardiovascular (including conduction abnormalities, myocarditis, heart failure, and CAD),…”
BackgroundImpact of Pretransplant Anti-HLA Antibodies on Outcomes in Lung Transplant Candidates
Kim, M., Townsend, K. R., Wood, I. G., Boukedes, S., Guleria, I., Gabardi, S., El-Chemaly, S., Camp, P. C., Chandraker, A. K., Milford, E. L., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2160oc · Cited by 72
Dobbels, F., Vanhaecke, J., Desmyttere, A., Dupont, L., Nevens, F., & Geest, S. D. (2005) · Transplantation · doi:10.1097/01.tp.0000158430.06507.87 · Cited by 70
Combined lung and liver transplantation: Analysis of a single-center experience
Yi, S. G., Burroughs, S. G., Loebe, M. M., Scheinin, S. A., Seethamraju, H., Jyothula, S., Monsour, H., McFadden, R., Podder, H., Saharia, A., et al. (2013) · Liver Transplantation · doi:10.1002/lt.23770 · Cited by 70 · cited 1×
“161 ,162 Severely impaired liver synthetic function with an albumin < 2.0 g/dl, INR > 1.8 or the presence of severe ascites or encephalopathy should be considered contraindications.”
BackgroundInfluentialSchaffer, J. M., Singh, S. K., Joyce, D. L., Reitz, B. A., Robbins, R. C., Zamanian, R. T., & Mallidi, H. R. (2013) · Circulation · doi:10.1161/circulationaha.112.001080 · Cited by 69
Villavicencio, M. A., Axtell, A. L., Osho, A. A., Astor, T., Roy, N., Melnitchouk, S. I., D’Alessandro, D. A., Tolis, G., Raz, Y., Neuringer, I. P., et al. (2018) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2018.04.060 · Cited by 68
Frailty trajectories in adult lung transplantation: a cohort study
Venado, A., McCulloch, C., Greenland, J. R., Katz, P., Soong, A., Shrestha, P., Hays, S., Golden, J., Shah, R., Leard, L. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.03.006 · Cited by 67 · cited 1×
“54 When considering frailty in lung transplant candidates, it should be noted that optimal assessment tools for frailty are not yet accepted and caution is warranted in using frailty for listing decisions.”
BackgroundSelf-citationHayes, D., Black, S. M., Tobias, J. D., Kirkby, S., Mansour, H. M., & Whitson, B. A. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.06.024 · Cited by 66
Simultaneous Thoracic and Abdominal Transplantation: Can We Justify Two Organs for One Recipient?
Wolf, J. H., Sulewski, M. E., Cassuto, J. R., Levine, M. H., Naji, A., Olthoff, K. M., Shaked, A. A., & Abt, P. L. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12291 · Cited by 65 · cited 1×
“153 Multi-organ transplant candidates have a higher waiting list mortality than individuals listed for single organ transplant 154 ; however, recipients who survive the difficult peri-operative period experience significant survival benefit, with favorable long-term survival.”
BackgroundMorisset, J., Vittinghoff, E., Lee, B. Y., Tonelli, R., Hu, X., Elicker, B. M., Ryu, J. H., Jones, K. D., Cerri, S., Manfredi, A., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.04.012 · Cited by 65
Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0308-z · Cited by 65
Factors Associated with Adherence to Treatment Regimens after Lung Transplantation
Teichman, B., Burker, E. J., Weiner, M., & Egan, T. M. (2000) · Progress in Transplantation · doi:10.7182/prtr.10.2.303p27p4406w71v7 · Cited by 65
Psychological symptom levels and their correlates in lung and heart-lung transplant recipients
Stilley, C. S., Amanda Dew, M., Stukas, A. A., Switzer, G. E., Manzetti, J. D., Keenan, R. J., & Griffith, B. P. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71189-8 · Cited by 64
Lo, W.-K., Goldberg, H. J., Wee, J., Fisichella, P. M., & Chan, W. W. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-2983-0 · Cited by 64 · cited 11×
“The most familiar of these is the BODE index [BMI, airflow limitation (forced expiratory volume in one second), dyspnea and 6-minute walk distance], which has been externally validated in at least 13 additional cohorts following the original derivation.”
BackgroundInfluentialLo, W.-K., Burakoff, R., Goldberg, H. J., Feldman, N., & Chan, W. W. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.005 · Cited by 64 · cited 1×
“Esophageal Dysfunction / Gastrointestinal Dysmotility/ Gastroesophageal reflux (GER): Post-transplant GER is variably associated with increased risk of acute rejection, pulmonary infection and earlier development of chronic lung allograft dysfunction (CLAD).(32,33) Anti-reflux surgery pre-transplant and early post-tra…”
BackgroundPrognostic value of six minute walk test in cystic fibrosis adults
Martin, C., Chapron, J., Hubert, D., Kanaan, R., Honoré, I., Paillasseur, J.-L., Aubourg, F., Dinh-Xuan, A.-T., Dusser, D., Fajac, I., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.10.001 · Cited by 63
Ribeiro Neto, M. L., Jellis, C. L., Joyce, E., Callahan, T. D., Hachamovitch, R., & Culver, D. A. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201902-119cme · Cited by 63
Guler, S. A., Kwan, J. M., Leung, J. M., Khalil, N., Wilcox, P., & Ryerson, C. J. (2019) · European Respiratory Journal · doi:10.1183/13993003.00647-2019 · Cited by 63
Psychosocial Issues in the Assessment and Management of Patients Undergoing Lung Transplantation
Barbour, K. A., Blumenthal, J. A., & Palmer, S. M. (2006) · CHEST Journal · doi:10.1378/chest.129.5.1367 · Cited by 61
Neurocognitive changes after lung transplantation
Smith, P. J., Rivelli, S., Waters, A., Reynolds, J., Hoyle, A., Flowers, M., Davis, R. D., Palmer, S. M., Mathew, J., Durheim, M., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-232oc · Cited by 60
Self-citationThe Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 Edition)
(2019) · Transplantation · doi:10.1097/tp.0000000000002540 · Cited by 60
Yang, H., Xiang, P., Zhang, E., Guo, W., Shi, Y., Zhang, S., & Tong, Z. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008909 · Cited by 59
A 3-year prognostic score for adults with cystic fibrosis
Nkam, L., Lambert, J., Latouche, A., Bellis, G., Burgel, P., & Hocine, M. N. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.03.004 · Cited by 59 · cited 2×
“254 In this model a score of ≥ 4 was associated with a 55% risk of 3-year mortality, whereas a score of ≤ 2 carried only a 1% risk.”
BackgroundOutcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Pulmonary transplantation for advanced bronchioloalveolar carcinoma
Zorn, G. L., McGiffin, D. C., Young, K. R., Alexander, C. B., Weill, D., & Kirklin, J. K. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2003.72 · Cited by 58 · cited 1×
“321,322,330 Modifying the surgical approach as suggested to reduce aerogenous contamination of donor lungs at the time of implantation may mitigate the risk of relapse post-transplant.”
BackgroundSelf-citationThe feasibility of lung transplantation in HIV-seropositive patients
Kern, R. M., Seethamraju, H., Blanc, P. D., Sinha, N., Loebe, M., Golden, J., Kukreja, J., Scheinin, S., Hays, S., Kleinhenz, M. E., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201402-083oc · Cited by 58
Self-citationLancaster, T. S., Miller, J. R., Epstein, D. J., DuPont, N. C., Sweet, S. C., & Eghtesady, P. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.10.007 · Cited by 58
Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices
Jacob, J., Bartholmai, B. J., Rajagopalan, S., et al. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.007 · Cited by 58
Kon, Z. N., Dahi, S., Evans, C. F., Byrnes, K. A., Bittle, G. J., Wehman, B., Rector, R. P., McCormick, B. M., Herr, D. L., Sanchez, P. G., et al. (2015) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.05.088 · Cited by 57
Hayanga, A. J., Aboagye, J. K., Hayanga, H. E., Morrell, M., Huffman, L., Shigemura, N., Bhama, J. K., D׳Cunha, J., & Bermudez, C. A. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.09.028 · Cited by 56 · cited 2×
“With increasing experience in older recipients, several studies have shown that carefully selected older recipients may have the same short-term survival as younger recipients.(9) However, the results are skewed by selection bias, reflecting the fact that most recipients over the age of 65 years undergoing lung transp…”
BackgroundColman, R., Singer, L. G., Barua, R., & Downar, J. (2015) · Palliative Medicine · doi:10.1177/0269216314566839 · Cited by 55 · cited 1×
“121,122 The risk and benefit of opioids prescribed to lung transplant candidates to palliate symptoms of pain or dyspnea should be considered on an individual basis.”
BackgroundProlonged Duration ECMO for ARDS: Futility, Native Lung Recovery, or Transplantation?
Rosenberg, A. A., Haft, J. W., Bartlett, R., Iwashyna, T. J., Huang, S. K., Lynch, W. R., & Napolitano, L. M. (2013) · ASAIO Journal · doi:10.1097/mat.0b013e3182a9e341 · Cited by 55
Heart or lung transplant outcomes in HIV-infected recipients
Koval, C. E., Farr, M., Krisl, J., Haidar, G., Pereira, M. R., Shrestha, N., Malinis, M. F., Mueller, N. J., Hannan, M. M., Grossi, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.09.011 · Cited by 55
Hypoalbuminemia and early mortality after lung transplantation: a cohort study
Baldwin, M. R., Arcasoy, S. M., Shah, A., Schulze, P. C., Sze, J., Sonett, J. R., & Lederer, D. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03965.x · Cited by 54 · cited 1×
“46-48 It is also a predictor of poor survival for lung transplant candidates while on the waiting list including those who require ECLS prior to lung transplant.”
BackgroundSelf-citationTechniques and results of lobar lung transplantations
Mitilian, D., Sage, É., Puyo, P., et al. (2013) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezt353 · Cited by 54 · cited 1×
“141,142 Other considerations : Significant chest wall abnormalities, spinal deformities, or mediastinal fibrosis require individualized evaluation to determine surgical feasibility and degree of restriction anticipated post-transplant.”
BackgroundBest practices in the pediatric pretransplant psychosocial evaluation
Lefkowitz, D. S., Fitzgerald, C. J., Zelikovsky, N., Barlow, K., & Wray, J. (2014) · Pediatric Transplantation · doi:10.1111/petr.12260 · Cited by 54
MONTGOMERY, E. E., Macdonald, P. S., Newton, P. J., Chang, S., Jha, S. R., Hannu, M. K., Thomson, C., Havryk, A. P., & Malouf, M. A. (2019) · Transplantation · doi:10.1097/tp.0000000000002901 · Cited by 52
Impact of nutritional state on lung transplant outcomes
Chamogeorgakis, T., Mason, D. P., Murthy, S. C., Thuita, L., Raymond, D. P., Pettersson, G. B., & Blackstone, E. H. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.04.005 · Cited by 51
Lung transplantation following 107 days of extracorporeal membrane oxygenation
Iacono, A., Groves, S., Garcia, J., & Griffith, B. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2009.09.039 · Cited by 51
Yoon, H., Kim, T. H., Seo, J. B., Lee, S. M., Lim, S., Lee, H. N., Kim, N., Han, M., Kim, D. S., & Song, J. W. (2018) · Respirology · doi:10.1111/resp.13387 · Cited by 51 · cited 1×
“210,211 Predicting prognosis for individual patients with ILD remains difficult.”
BackgroundSmith, P. J., Snyder, L. D., Palmer, S. M., Hoffman, B. M., Stonerock, G. L., Ingle, K., Saulino, C. K., & Blumenthal, J. A. (2017) · Transplant International · doi:10.1111/tri.13094 · Cited by 51
Self-citationWeight loss prior to lung transplantation is associated with improved survival
Chandrashekaran, S., Keller, C. A., Kremers, W. K., Peters, S. G., Hathcock, M. A., & Kennedy, C. C. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2014.11.018 · Cited by 50 · cited 1×
“43,44 While low BMI has been associated with increased mortality, Cystic fibrosis (CF) recipients with BMI 17 kg/m 2 have a survival rate similar to other commonly transplanted patients.”
BackgroundDelirium affects length of hospital stay after lung transplantation
Smith, P. J., Rivelli, S. K., Waters, A. M., Hoyle, A., Durheim, M. T., Reynolds, J. M., Flowers, M., Davis, R. D., Palmer, S. M., Mathew, J. P., et al. (2015) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.09.010 · Cited by 49
Self-citationLung transplantation for advanced bronchioloalveolar carcinoma confined to the lungs
Paloyan, E. B., Swinnen, L. J., Montoya, A., Lonchyna, V., Sullivan, H. J., & Garrity, E. (2000) · Transplantation · doi:10.1097/00007890-200006150-00041 · Cited by 49 · cited 1×
“323,331 In summary, the risk associated with lung transplant in candidates with thoracic malignancy is high, and each center therefore needs to consider whether the possible benefit outweighs this risk and balance the overall need for prioritization of transplantable organs.”
BackgroundHeart–lung vs. double‐lung transplantation for idiopathic pulmonary arterial hypertension
Hill, C. C., Maxwell, B. G., Boulate, D., Haddad, F., Ha, R. V., Afshar, K., Weill, D., & Dhillon, G. S. (2015) · Clinical Transplantation · doi:10.1111/ctr.12628 · Cited by 48
Self-citationChakinala, M. M., Coyne, D. W., Benza, R. L., Frost, A. E., McGoon, M. D., Hartline, B. K., Frantz, R. P., Selej, M., Zhao, C., Mink, D. R., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.10.028 · Cited by 48
Survival in pulmonary arterial hypertension patients awaiting lung transplantation
Gomberg-Maitland, M., Glassner-Kolmin, C., Watson, S., Frantz, R., Park, M., Frost, A., Benza, R. L., & Torres, F. (2013) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2013.08.016 · Cited by 47
Psychosocial Challenges in Solid Organ Transplantation
Kuntz, K., Weinland, S. R., & Butt, Z. (2015) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-015-9435-6 · Cited by 47
The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis
Nishimoto, K., Fujisawa, T., Yoshimura, K., Enomoto, Y., Enomoto, N., Nakamura, Y., Inui, N., Sumikawa, H., Johkoh, T., Colby, T. V., et al. (2018) · Respirology · doi:10.1111/resp.13219 · Cited by 47
Smith, P. J., Blumenthal, J. A., Hoffman, B. M., Rivelli, S. K., Palmer, S. M., Davis, R. D., & Mathew, J. P. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201507-454oc · Cited by 46
Self-citationAssociation of chronic obstructive pulmonary disease with mild cognitive impairment and dementia
Kakkera, K., Padala, K. P., Kodali, M., & Padala, P. R. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000458 · Cited by 46
Badagliacca, R., Papa, S., Poscia, R., Valli, G., Pezzuto, B., Manzi, G., Torre, R., Gianfrilli, D., Sciomer, S., Palange, P., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2018.11.015 · Cited by 46 · cited 1×
“289,290 Furthermore, specific clinical scenarios known to equate to a high-risk profile need to be considered.”
BackgroundBaldwin, M. R., Singer, J. P., Huang, D., Sell, J., Gonzalez, W. C., Pollack, L. R., Maurer, M. S., D’Ovidio, F. F., Bacchetta, M., Sonett, J. R., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201612-1008oc · Cited by 45
Self-citation
Flagged first, then by citations
14 of the 363 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kulig, 2017, Interpretation of workplace tests for cannabinoids, J Med Toxicol, 13, 106, 10.1007/s13181-016-0587-z · DOI · Paper page
Cited by
Sorted by citations
Wijsenbeek, M. S., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 576
Self-citationMaher, T. M. (2024) · JAMA · doi:10.1001/jama.2024.3669 · Cited by 429
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Bhakta, N. R., Bime, C., Kaminsky, D. A., McCormack, M. C., Thakur, N., Stanojevic, S., Baugh, A. D., Braun, L., Lovinsky‐Desir, S., Adamson, R., et al. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202302-0310st · Cited by 316
“…is not used in the lung allocation score, the timing and listing for lung transplantation depends on — although it is not exclusively dependent on — FEV 1 (for COPD, cystic fi brosis, and lymphangioleiomyomatosis) and FVC (for interstitial lung disease) as a percentage of the predicted value (92).”
Progressive pulmonary fibrosis: an expert group consensus statement
Rajan, S. K., Cottin, V., Dhar, R., Danoff, S. K., Flaherty, K. R., Brown, K. K., Mohan, A., Renzoni, E. A., Mohan, M., V, Udwadia, Z., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.03187-2021 · Cited by 271
Agarwal, R., Sehgal, I. S., Muthu, V., Denning, D. W., Chakrabarti, A., Kathirvel, S., Garg, M. K., Rudramurthy, S. M., Dhooria, S., Armstrong-James, D. P. H., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00061-2024 · Cited by 291
“The International Society for Heart and Lung Transplantation criteria should be used to refer and list patients with advanced ABPA [172].”
Pulmonary fibrosis: from pathogenesis to clinical decision-making
Koudstaal, T., Funke-Chambour, M., Kreuter, M., Molyneaux, P. L., & Wijsenbeek, M. S. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.08.010 · Cited by 268
Self-citationPeled, Y., Ducharme, A., Kittleson, M. M., Bansal, N., Stehlik, J., Amdani, S. M., Saeed, D., Cheng, R., Clarke, B. A., Dobbels, F., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.05.010 · Cited by 279
Boucly, A., Weatherald, J. C., Savale, L., de Groote, P., Cottin, V., Prévôt, G., Chaouat, A., Picard, F., Horeau-Langlard, D., BOURDIN, A. A., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.02419-2021 · Cited by 211
Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 236
Olsson, K. M., Corte, T. J., Kamp, J. C., Montani, D., Nathan, S. D., Neubert, L., Price, L., & Kiely, D. G. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00259-x · Cited by 148
Diagnosis, course and management of hypersensitivity pneumonitis
Hamblin, M., Prosch, H., & Vašáková, M. (2022) · European Respiratory Review · doi:10.1183/16000617.0169-2021 · Cited by 147
Pulmonary hypertension associated with lung diseases
Shlobin, O. A., Adir, Y., Barberà, J. A., Cottin, V., Harari, S. A., Jutant, E., Pepke‐Żaba, J., Ghofrani, H. A., & Channick, R. N. (2024) · European Respiratory Journal · doi:10.1183/13993003.01200-2024 · Cited by 159
“In appropriate candidates, patients with bronchiectasis and PH should be referred for lung transplantation workup [162].”
Self-citationIdiopathic pulmonary fibrosis.
Koudstaal, T., & Wijsenbeek, M. S. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104166 · Cited by 105
Self-citationKoduri, G., & Solomon, J. J. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42640 · Cited by 108
“Guidelines recommend that patients who have severe and progressive RA-ILD that has not responded to appropriate treat-ment and who do not have extrapulmonary contraindications should be considered for lung transplantation (107).”
BackgroundExpected effect of the lung Composite Allocation Score system on US lung transplantation
Valapour, M., Lehr, C., Wey, A., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17160 · Cited by 78
“16 Development of the CAS provided an opportunity to be explicit about prioritization of ethical principles in the lung transplantation system, 17 with components selected through a hybrid approach using multicriteria decision-making methodologies and an analytical hierarchy process to elicit…”
MethodSelf-citationChristie, J. D., Raemdonck, D. E. V., & Fisher, A. J. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2401039 · Cited by 108
Lung transplantation for interstitial lung disease
Kapnadak, S. G., & Raghu, G. (2021) · European Respiratory Review · doi:10.1183/16000617.0017-2021 · Cited by 98
Self-citationEuropean Respiratory Society statement on frailty in adults with chronic lung disease
Osadnik, C. R., Brighton, L. J., Burtin, C., Cesari, M., Lahousse, L., Man, W. D., Marengoni, A., Šajnić, A., Singer, J. P., ter Beek, L., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00442-2023 · Cited by 96
“…for Heart and Lung Transplantation international consensus document for selection of lung transplant candidates states that frailty assessment should be considered part of a comprehensive transplant evaluation in recognition of its negative impact upon waitlist and post-transplant mortality [16].”
BackgroundBurgel, P., Southern, K. W., Addy, C., Battezzati, A., Berry, C. A., Bouchara, J., Brokaar, E. J., Brown, A. W., Azevedo, P., Durieu, I., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.01.005 · Cited by 101
“Assessment of lung transplant candidates by transplant teams have been the subject of consensus documents [193] and practical guidelines [194], recognizing the specific needs of people with CF. Determining the optimal timing for lung transplantation remains difficult and may differ between…”
BackgroundGroup 3 Pulmonary Hypertension: From Bench to Bedside
Singh, N., Dorfmüller, P., Shlobin, O. A., & Ventetuolo, C. E. (2022) · Circulation Research · doi:10.1161/circresaha.121.319970 · Cited by 88
Self-citationMartin, C., Reynaud‐Gaubert, M., Hamidfar, R., Durieu, I., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., Grenet, D., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.01.012 · Cited by 67
Nikkho, S. M., Richter, M. J., Shen, E., Abman, S. H., Antoniou, K., Chung, J. H., Fernandes, P., Hassoun, P. M., Lazarus, H. M., Olschewski, H., et al. (2022) · Pulmonary Circulation · doi:10.1002/pul2.12127 · Cited by 70
Self-citationMcCarthy, C., Bonella, F., O’Callaghan, M., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.00725-2024 · Cited by 63
Reproductive health after thoracic transplantation: An ISHLT expert consensus statement
Kittleson, M. M., DeFilippis, E. M., Bhagra, C., Casale, J. P., Cauldwell, M., Coscia, L. A., D'Souza, R. D., Gaffney, N., Gerovasili, V., Ging, P., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.10.009 · Cited by 67
Mackintosh, J. A., Keir, G. J., Troy, L. K., Holland, A. E., Grainge, C., Chambers, D. C., Sandford, D., Jo, H. E., Glaspole, I., WILSHER, M. L., et al. (2024) · Respirology · doi:10.1111/resp.14656 · Cited by 54
Idiopathic inflammatory myopathies related lung disease in adults
Sehgal, S., Patel, A., Chatterjee, S., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00267-4 · Cited by 55
Mortality of patients with COPD
Halpin, D. M. G. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2375416 · Cited by 57
“The guidelines therefore recommend that they should be listed for transplantation if otherwise suitable [135].”
Sarcoidosis-associated pulmonary fibrosis: joining the dots
Bandyopadhyay, D., & Mirsaeidi, M. S. (2023) · European Respiratory Review · doi:10.1183/16000617.0085-2023 · Cited by 55
The changing landscape of pediatric lung transplantation
Avdimiretz, N., & Benden, C. (2022) · Clinical Transplantation · doi:10.1111/ctr.14634 · Cited by 49
Burgel, P., Paillasseur, J.-L., Durieu, I., Reynaud‐Gaubert, M., Hamidfar, R., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1065oc · Cited by 47
Slambrouck, J. V., Raemdonck, D. E. V., Vos, R., Vanluyten, C., Vanstapel, A., Prisciandaro, E., Willems, L., Orlitová, M., Kaes, J., Jin, X., et al. (2022) · Cells · doi:10.3390/cells11040745 · Cited by 50
“A more in-depth analysis on treatment and prevention of PGD goes beyond the scope of this focus review and was summarized elsewhere [3,6,34,36,37].”
BackgroundTransplantation, bridging, and support technologies in pulmonary hypertension
Savale, L., Benazzo, A., Corris, P. A., Keshavjee, S. H., Levine, D. J., Mercier, O. M., Davis, R. D., & Granton, J. T. (2024) · European Respiratory Journal · doi:10.1183/13993003.01193-2024 · Cited by 47
“The suitability of a patient for transplant should be made by the transplant programme in collaboration with the PH team based on current accepted standards for recipient selection [79].”
Barbosa, M. T. R., & Chalmers, J. D. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104174 · Cited by 45
Martin, A. K., Mercier, O. M., Fritz, A. V., Gelzinis, T. A., Höetzenecker, K., Lindstedt, S., Marczin, N., Wilkey, B., Schecter, M. G., Lyster, H. S., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.08.027 · Cited by 46
Self-citationSwaminathan, A. C., Hellkamp, A. S., Neely, M. L., Bender, S. D., Paoletti, L., White, E. S., Palmer, S. M., Whelan, T. P. M., & Dilling, D. F. (2022) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202105-589oc · Cited by 39
Lehmann, M., Krishnan, R., Sucre, J. M. S., Kulkarni, H. S., Pineda, R., Anderson, C., Banovich, N. E., Behrsing, H. P., Dean, C. H., Haak, A. J., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0479st · Cited by 45
Lung transplantation for COPD/pulmonary emphysema
Verleden, G. M., & Gottlieb, J. (2023) · European Respiratory Review · doi:10.1183/16000617.0116-2022 · Cited by 42
Sawinski, D. L., Lai, J. C., Pinney, S., Gray, A., Jackson, A. M., Stewart, D. E., Levine, D. J., Locke, J. E., Pomposelli, J. J., Hartwig, M. G., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.11.008 · Cited by 38
Self-citationCheng, X., Jiang, S., Pan, B., Xie, W., & Meng, J. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01964-3 · Cited by 39
“Lung transplantation is an effective treatment option for patients with end-stage IPF, but it is limited to a relatively young and healthy subset of patients [3].”
BackgroundBos, S., Murray, J. A., Marchetti, M., Cheng, G., Bergeron, A., Wolff, D., Sander, C. R., Sharma, A., Badawy, S. M., Perić, Z., et al. (2024) · European Respiratory Journal · doi:10.1183/13993003.01727-2023 · Cited by 37
Mudde, S. E., Schildkraut, J. A., Ammerman, N. C., de Vogel, C. P., de Steenwinkel, J. E. M., van Ingen, J., & Bax, H. I. (2022) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2022.10.015 · Cited by 34
Ringshausen, F. C., Sauer‐Heilborn, A., Büttner, T., Dittrich, A., Schwerk, N., Ius, F., Nährlich, L., Welte, T., & Greer, M. (2022) · European Respiratory Journal · doi:10.1183/13993003.01402-2022 · Cited by 34
Nathan, S. D., Chandel, A., Wang, Y., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.11.005 · Cited by 33
Development of the Lung Transplant Frailty Scale (LT-FS)
Singer, J. P., Christie, J. D., Diamond, J. M., Anderson, M. A., Benvenuto, L. J., Gao, Y., Arcasoy, S. M., Lederer, D. J., Calabrese, D. R., Wang, P., et al. (2023) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2023.02.006 · Cited by 33
Self-citationLung Transplantation for Pulmonary Arterial Hypertension
Kolaitis, N. A. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.04.047 · Cited by 37
Self-citationGholamzadeh, M., Abtahi, H., & Safdari, R. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01823-2 · Cited by 30
“By 2019, more than 4,500 lung transplants were executed at 260 centers worldwide, according to the International Heart and Lung Transplant Association (ISHLT) [4].”
BackgroundSchiavi, E., Ryu, M. H., Martini, L., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202311-2145oc · Cited by 24
Marinescu, D.-C., Hague, C. J., Müller, N. L., Murphy, D. T., Churg, A., Wright, J. L., Al-Arnawoot, A., Bilawich, A.-M., Bourgouin, P., Cox, G., et al. (2025) · Radiology · doi:10.1148/radiol.241001 · Cited by 30
Arslan, A., Smith, J., Qureshi, M. R., Uysal, A., Patel, K., Herazo‐Maya, J. D., & Bandyopadhyay, D. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1306032 · Cited by 25
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 25
Self-citationLung transplantation for interstitial lung disease: evolution over three decades
Leong, S. W., Bos, S., Lordan, J. L., Nair, A., Fisher, A. J., & Meachery, G. J. (2023) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001387 · Cited by 24
The Role of Pulmonary Function Testing in the Diagnosis and Management of COPD
Haynes, J. M., Kaminsky, D. A., & Ruppel, G. L. (2023) · Respiratory Care · doi:10.4187/respcare.10757 · Cited by 27
Subphenotypes of frailty in lung transplant candidates
Singer, J. P., Calfee, C. S., Delucchi, K., Diamond, J. M., Anderson, M. A., Benvenuto, L. A., Gao, Y., Wang, P., Arcasoy, S. M., Lederer, D. J., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.01.020 · Cited by 25
Self-citationKolaitis, N. A., Chen, H., Calabrese, D. R., Kumar, K., Obata, J., Bach, C., Golden, J. A., Simon, M. A. M., Kukreja, J., Hays, S. R., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0217oc · Cited by 23
Self-citationHansmann, G., Diekmann, F., Chouvarine, P., Ius, F., Carlens, J., Schwerk, N., Warnecke, G., Vogel‐Claussen, J., Hohmann, D., Alten, T. A., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.014 · Cited by 22
Stepanova, M., Kumar, A. R., Brandt, P., Gundurao, N., Cusi, K. J., Qahtani, S. A., & Younossi, Z. M. (2023) · Diabetes Care · doi:10.2337/dc23-1085 · Cited by 19
Ghanem, O. M., Pita, A., Nazzal, M., Johnson, S. M., Diwan, T. S., Obeid, N. R., Croome, K. P., Lim, R., Quintini, C., Whitson, B. A., et al. (2024) · Surgical Endoscopy · doi:10.1007/s00464-024-10930-8 · Cited by 20
“The latest Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation criteria of eligibility included a BMI of ≥ 35 kg/m 2 as a relative contraindication for lung transplantation [72].”
BackgroundThomas, J., Chen, Q., Malas, J., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.01.014 · Cited by 20
Frailty predicts outcomes in cystic fibrosis patients listed for lung transplantation
Koutsokera, A., Sykes, J. R., Theou, O., Rockwood, K. J., Steinack, C., Derkenne, M.-F., Benden, C., Krueger, T., Chaparro, C., Aubert, J., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.07.017 · Cited by 21
“7) 28 (18-54) Age at LT, years 30 (18-63) 29 (18-56) Time on the waitlist, days 68.”
Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
Janić, M., Škrgat, S., Harlander, M., Lunder, M., Janež, A., Stoian, A. P., El‐Tanani, M., Maggio, V., & Rizzo, M. (2024) · Medicina · doi:10.3390/medicina60122030 · Cited by 27
“GLP-1 receptor agonists can be used in weight loss strategies prior to lung transplantation [96], as it has been shown that mortality risk increases with BMI > 35 kg/m 2 and that the magnitude of pre-transplant weight loss is directly correlated with improved post-transplant survival [97].”
Donor to recipient age matching in lung transplantation: A European experience
Pradère, P., Pavec, J. L., Morisset, S., Gerovasili, V., Kessler, R., Adlakha, A., Bunel, V., Santhanakrishnan, K., Demant, X., Roux, A., et al. (2024) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2024.06.008 · Cited by 19
Luu, H. Y., Santos, J., Isaza, E., Brzeziński, M., & Kukreja, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1387 · Cited by 18
“While approximately 5% of recipients in the UNOS registry are reported to require ECLS post-LTx (8), this number is likely to increase in the future as higher-risk candidates become prioritized on the waitlist (27).”
Porras, M. C., Cuesta, V. M. M., Fernandez, D. I., et al. (2022) · Clinical Transplantation · doi:10.1111/ctr.14832 · Cited by 18
Bourgeois, N., Shallwani, S. M., Al-Huda, F. S., Mathur, S., Poirier, C. D., & Janaudis‐Ferreira, T. (2022) · Transplantation Direct · doi:10.1097/txd.0000000000001385 · Cited by 19
Wu, J., Li, C., Gao, P., Zhang, C., Zhang, P., Zhang, L., Dai, C., Zhang, K., Shi, B., Liu, M., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01515-3 · Cited by 17
“INTRODUCTION Lung transplantation is a potentially curative therapy for patients with end-stage pulmonary disease.(1) Nevertheless, the overall survival after a lung transplant is still inferior compared to other solid-organ transplantation modalities.”
BackgroundGhanem, O. M., Pita, A., Nazzal, M., Johnson, S. M., Diwan, T. S., Obeid, N. R., Croome, K. P., Lim, R., Quintini, C., Whitson, B. A., et al. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.04.013 · Cited by 17
Evolving Nutritional Needs in Cystic Fibrosis
Frantzen, T., Barsky, S., LaVecchia, G., Marowitz, M., & Wang, J. (2023) · Life · doi:10.3390/life13071431 · Cited by 18
“Continuous folic acid supplementation for at least 12 weeks and regular follow up with a CF dietitian is recommended [79].”
BackgroundOutcomes of Lung Transplant Candidates Aged ≥70 Years During the Lung Allocation Score Era
Zhou, A. L., Karius, A. K., Ruck, J. M., Shou, B. L., Larson, E. L., Casillan, A. J., Ha, J. S., Shah, P. D., Merlo, C. A., & Bush, E. L. (2023) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2023.04.046 · Cited by 17
Ehrsam, J. P., Schuurmans, M. M., Laager, M., Opitz, I., & İnci, İ. (2022) · Transplant International · doi:10.3389/ti.2022.10451 · Cited by 18
Lung transplantation in HIV-positive patients: a European retrospective cohort study
Rouzaud, C., Berastegui, C., Picard, C., Vos, R., Savale, L., Demant, X., Bertani, A., Verschuuren, E. A. M., Jaksch, P., Reed, A. K., et al. (2022) · European Respiratory Journal · doi:10.1183/13993003.00189-2022 · Cited by 19
Hayes, D., Avdimiretz, N., Brugha, R. E., Mullen, M. P., Paraskeva, M. A., Mıdyat, L., Solomon, M. P., Sweet, S. C., Melicoff, E., Danziger‐Isakov, L. A., et al. (2025) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2025.08.005 · Cited by 19
Self-citationObesity and Extracorporeal Membrane Oxygenation (ECMO): Analysis of Outcomes
Ripoll, J. G., ElSaban, M., Nabzdyk, C. S., Balakrishna, A., Villavicencio, M. A., Calderon-Rojas, R. D., Ortoleva, J. P., Chang, M. G., Bittner, E. A., & Ramakrishna, H. (2023) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2023.10.025 · Cited by 16
Chandel, A., King, C. S., Ignacio, R. V., Pastré, J., Shlobin, O. A., Khangoora, V. S., Aryal, S., NYQUIST, A. S., SINGHAL, A. L., Flaherty, K. R., et al. (2023) · ERJ Open Research · doi:10.1183/23120541.00124-2023 · Cited by 17
Self-citationKuczewski, M. G., Wasson, K., Hutchison, P. J., & Dilling, D. F. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.10.001 · Cited by 16
“Many of these are well-known such as requiring potential recipients of a liver transplant who suffer from alcohol substance use disorder to complete a treatment program for the disorder or for a cigarette smoker to demonstrate a sustained abstinence from nicotine before he is approved for a lung transplant.(6) Such re…”
BackgroundLung transplantation for lymphangioleiomyomatosis
Warrior, K., & Dilling, D. F. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.09.021 · Cited by 15
Interstitial Lung Disease in Rheumatoid Arthritis: A Review
AL-Baldawi, S. A. A., Salazar, G. Z., Zúñiga, D., Balasubramanian, S., & Mehmood, K. T. (2024) · Cureus · doi:10.7759/cureus.53632 · Cited by 16
“Lung transplantation should be considered for patients with severe and progressive RA-ILD who do not have extrapulmonary contraindications and who have not responded to appropriate treatment [76].”
BackgroundMangseth, H., Sikkeland, L. I. B., Durheim, M. T., et al. (2023) · BMC Pulmonary Medicine · doi:10.1186/s12890-023-02430-7 · Cited by 15
Extracorporeal life support as a bridge to lung transplantation: Where are we now?
Patterson, C. M., Shah, A. M., Rabin, J., DiChiacchio, L., Cypel, M., Höetzenecker, K., Catarino, P., & Lau, C. L. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.004 · Cited by 17
Self-citationVicaire, H., Pavec, J. L., Mercier, O. M., Montani, D., Boucly, A., Roche, A., Pradère, P., Dauriat, G., Feuillet, S., Pichon, J., et al. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.06.001 · Cited by 16
Lehr, C. J., Wey, A. R., Skeans, M. A., Lease, E. D., & Valapour, M. (2022) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2022.02.012 · Cited by 16
“”(8) These principles were also upheld by the recently published International Society for Heart and Lung Transplantation guidelines on the selection of lung transplant candidates and the systems that allocate donor lungs.(25) This statement considered the principle of utility on the societal level and made recommenda…”
BackgroundSelf-citationChanges in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Oldham, J. M., Neely, M. L., WOJDYLA, D. M., Gulati, M., Li, P., Patel, D. C., Palmer, S. M., & Todd, J. L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.02.018 · Cited by 20
Otani, I. M., & Ballow, M. C. (2024) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2024.12.024 · Cited by 15
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis
Keith, R. C., & Nambiar, A. M. (2025) · Therapeutic Advances in Respiratory Disease · doi:10.1177/17534666241309795 · Cited by 20
“…a progressive phenotype, including fibrosing HP. Lung transplantation can improve the quality of life and survival in patients with IPF and PPF. 74,75 However, lung transplantation is only a viable option for a minority of patients with IPF/PPF. Factors such as age, comorbidities, overall health,…”
Herpes Virus Infection in Lung Transplantation: Diagnosis, Treatment and Prevention Strategies
Patrucco, F., Curtoni, A., Sidoti, F., Zanotto, E., Bondi, A., Albera, C., Boffini, M., Cavallo, R., Costa, C. S., & Solidoro, P. (2023) · Viruses · doi:10.3390/v15122326 · Cited by 14
“Lung transplantation represents a viable treatment option for many end-stage lung diseases [1]; chronic lung allograft dysfunction (CLAD), resulting in bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS), is the most representative cause of mortality after the first year…”
Elia, D., Cassandro, R., Caminati, A., Luisi, F., & Harari, S. A. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104173 · Cited by 14
Lung Transplantation in a New Era in the Field of Cystic Fibrosis
Huang, W., Smith, A., Korotun, M., Iacono, A. T., & Wang, J. (2023) · Life · doi:10.3390/life13071600 · Cited by 15
“For example, referral criteria for patients who suffer from chronic obstructive pulmonary disease (COPD) include having a BODE index [19], a composite score measuring body mass index, forced expiratory volume in one second (FEV1), dyspnea, and six-minute walk distance equal to five or six with other features of increa…”
BackgroundMethodInfluentialPison, C., Tissot, A., Bernasconi, E., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1126697 · Cited by 13
The Management of Interstitial Lung Disease in the ICU: A Comprehensive Review
Dhanani, Z., & Gupta, R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226657 · Cited by 15
Virtual Physical Prehabilitation in Lung Transplant Candidates: A Proof-of-Concept Study
Bourgeois, N., Lands, L. C., Prévost, K., Poirier, C. D., & Janaudis‐Ferreira, T. (2024) · Transplant International · doi:10.3389/ti.2024.12355 · Cited by 14
Bordas-Martínez, J., Miedema, J., Mathot, B. J., Seghers, L., Galjaard, R. H., Raaijmakers, M. H. G. P., Aalbers, A. M., Wijsenbeek, M. S., Molina‐Molina, M., & Hellemons, M. E. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100054 · Cited by 13
“…available on how to handle patients with trILD, apart from the advice that patients with telomeropathy should “undergo detailed evaluation,” 28 it will differ between transplant centers how the results of such evaluation are weighed, affecting patient selection and therewith…”
Self-citationRadtke, T., Urquhart, D. S., Braun, J., Barry, P. J., Waller, I., Petch, N., Mei‐Zahav, M., Kramer, M. R., Hua-Huy, T., Dinh‐Xuan, A. T., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202304-317oc · Cited by 13
Latorre‐Rodríguez, A. R., Razia, D., Omar, A. A., et al. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100796 · Cited by 13
Campagna, B. R., & Annunziato, R. A. (2023) · Pediatric Transplantation · doi:10.1111/petr.14497 · Cited by 14
Ding, Q., Chen, W., Chen, G., Zhu, Y., Yang, W.-W., & Ding, J.-R. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3125 · Cited by 12
“However, in the scoring standards recognized for recipient selection among patients with ESLD worldwide, there is a lack of focus on nutritional status (20-22).”
Zysman, M., Mahay, G., Guibert, N. M., Barnig, C., Leroy, S., & Guilleminault, L. (2023) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2023.101035 · Cited by 15
Clinical Course of Interstitial Lung Disease in Patients With Rheumatoid Arthritis
Matteson, E. L., Bendstrup, E. M., Strek, M. E., & Dieudé, P. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11736 · Cited by 12
Interstitial Lung Disease Associated with Systemic Sclerosis
Mismetti, V., Si-Mohamed, S. A., & Cottin, V. (2024) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0044-1786698 · Cited by 14
Japanese guidelines for the treatment of idiopathic pulmonary fibrosis 2023:Revised edition
Bando, M., Homma, S., Date, H., Kishi, K., Yamauchi, H., Sakamoto, S., Miyamoto, A., Goto, Y., Nakayama, T., Azuma, A., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.02.014 · Cited by 12
Progressive Pulmonary Fibrosis: Where Are We Now?
Kang, H. K., & Song, J. W. (2023) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2023.0119 · Cited by 17
“However, because these studies were retrospective and limited by selection bias, ISHLT considers CTD to be a risk factor for poorer outcomes and recommends screening for extrapulmonary disease in collaboration with a multidisciplinary team 72,73 .”
Background
Metadata
- Authors
- Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., Hartwig, M. G., Kapnadak, S. G., Kolaitis, N. A., Kotloff, R. M., Patterson, C. M., Shlobin, O. A., Smith, P. J., Solé, A., Solomon, M., Weill, D., Wijsenbeek, M. S., Willemse, B. W. M., Arcasoy, S. M., & Ramos, K. J.
- Affiliations
- University of California, San Francisco (US)
- Oslo University Hospital (NO)
- Cleveland Clinic (US)
- St Vincent's Hospital Sydney (AU)
- Krishna Institute of Medical Sciences (IN)
- University of Toronto (CA)
- Medical University of South Carolina (US)
- Sahlgrenska University Hospital (SE)
- Duke University (US)
- University of Washington (US)
- University of Pennsylvania (US)
- Royal Papworth Hospital (GB)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- University Medical Center Groningen (NL)
- Columbia University (US)
- Corresponding author
- Leard, Lorriana E.
- ORCID
- Leard, Lorriana E.
- Holm, Are M.
- Valapour, Maryam
- Glanville, Allan R.
- Attawar, Sandeep
- Aversa, Meghan
- Christon, Lillian M.
- Cypel, Marcelo
- Dellgren, Göran
- Hartwig, Matthew G.
- Kapnadak, Siddhartha G.
- Kolaitis, Nicholas A.
- Patterson, Caroline M.
- Shlobin, Oksana A.
- Smith, Patrick J.
- Solomon, Melinda
- Wijsenbeek, Marlies S.
- Willemse, Brigitte W.M.
- Arcasoy, Selim M.
- Ramos, Kathleen J.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 40
- Issue
- 11
- Pages
- 1349-1379
- ISSN
- 1053-2498 (ISSN-L)
- PMC
- PMC8979471
- OpenAlex
- W3183806681
- Semantic Scholar
- 428c0f28db10a88c62c6b907d2c92a02bac6b503
- Cited by
- 821
- References
- 363
- Citations by year
- 2026: 170 · 2025: 181 · 2024: 186 · 2023: 176 · 2022: 97 · 2021: 11
- FWCI
- 110.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Heart and Lung Transplantation (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Cystic Fibrosis Foundation
- Boomer Esiason Foundation
- Bristol-Myers Squibb
- United Therapeutics Corporation
- European Respiratory Society
- Vertex Pharmaceuticals
- Savara Pharmaceuticals
- Galecto
- ZonMw
- Astellas Pharma
- Lung Foundation Netherlands
- National Institutes of Health
- Health Resources and Services Administration
- National Heart, Lung, and Blood Institute (K23HL138154)
- Topics
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Organ Donation and Transplantation
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lung transplantation, transplant candidate selection, advanced lung disease, referral timing, transplant evaluation, transplant listing, transplant ethics, risk stratification, International Society for Heart and Lung Transplantation
- MeSH terms
- Contraindications, Cystic Fibrosis, Humans, Societies, Medical, Lung Transplantation, Patient Selection, Pulmonary Disease, Chronic Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-25 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
